Updated on 2024/03/29

写真a

 
SHIBASAKI Yasuhiko
 
Organization
University Medical and Dental Hospital Hematology Lecturer
Title
Lecturer
External link

Degree

  • 博士(医学) ( 2006.3   新潟大学 )

Research Areas

  • Life Science / Hematology and medical oncology

Research History (researchmap)

  • 新潟大学医歯学総合病院   血液内科   講師

    2017.4

      More details

  • 新潟大学医歯学総合病院   高密度無菌治療部   助教

    2013.6 - 2017.3

      More details

Research History

  • Niigata University   University Medical and Dental Hospital Hematology   Lecturer

    2017.4

  • Niigata University   University Medical and Dental Hospital Bone Marrow Transplantation Division   Assistant Professor

    2013.6 - 2017.3

Education

  • Niigata University   大学院医師学総合研究科   生体機能調節医学専攻機能再建医学講座血液学分野

    2002.4 - 2006.3

      More details

  • Niigata University   Faculty of Medicine   School of Medicine

    1993.4 - 1999.3

      More details

Professional Memberships

Committee Memberships

  • Japanese Society for Transplantation and Cellular Therapy   councillor  

    2020.4   

      More details

    Committee type:Academic society

    researchmap

 

Papers

  • Genetic manipulation resulting in decreased donor chondroitin sulfate synthesis mitigates hepatic GVHD via suppression of T cell activity. International journal

    Suguru Tamura, Hajime Ishiguro, Tatsuya Suwabe, Takayuki Katagiri, Kaori Cho, Kyoko Fuse, Yasuhiko Shibasaki, Tadahisa Mikami, Takero Shindo, Hiroshi Kitagawa, Michihiro Igarashi, Hirohito Sone, Masayoshi Masuko, Takashi Ushiki

    Scientific reports   13 ( 1 )   13098 - 13098   2023.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Donor T cell activation, proliferation, differentiation, and migration are the major steps involved in graft-versus-host disease (GVHD) development following bone marrow transplantation. Chondroitin sulfate (CS) proteoglycan is a major component of the extracellular matrix and causes immune modulation by interacting with cell growth factors and inducing cell adhesion. However, its precise effects on immune function are unclear than those of other proteoglycan families. Thus, we investigated the significance of CS within donor cells in acute GVHD development utilizing CSGalNAc T1-knockout (T1KO) mice. To determine the effects of T1KO, the mice underwent allogenic bone marrow transplantation from major histocompatibility complex-mismatched donors. While transplantation resulted in hepatic GVHD with inflammatory cell infiltration of both CD4+ and CD8+ effector memory T cells, transplantation in T1KO-donors showed milder cell infiltration and improved survival with fewer splenic effector T cells. In vitro T-cell analyses showed that the ratio of effector memory T cells was significantly lower via phorbol myristate acetate/ionomycin stimulation. Moreover, quantitative PCR analyses showed significantly less production of inflammatory cytokines, such as IFN-γ and CCL-2, in splenocytes of T1KO mice. These results suggest that reduction of CS in donor blood cells may suppress the severity of acute GVHD after hematopoietic stem cell transplantation.

    DOI: 10.1038/s41598-023-40367-3

    PubMed

    researchmap

  • ヘパプラスチンテストを取り入れた出血原因鑑別の検査戦略 後天性第V因子欠乏症における経験

    松田 将門, 山田 隆, 古山 悠里, 柴崎 康彦, 関 義信, 星山 良樹, 寺井 崇二, 瀧澤 淳, 曽根 博仁, 増子 正義

    日本血栓止血学会誌   34 ( 2 )   262 - 262   2023.5

     More details

    Language:Japanese   Publisher:(一社)日本血栓止血学会  

    researchmap

  • 妊娠初期における母体のヘモグロビン値・赤血球恒数と低出生体重児出産との関連の検討

    谷内 洋子, 坂本 莉菜, 柴崎 康彦, 山田 貴穂, 生魚 薫, 柳生田 紀子, 龍野 一郎, 曽根 博仁

    Journal of Epidemiology   33 ( Suppl.1 )   146 - 146   2023.2

     More details

    Language:Japanese   Publisher:(一社)日本疫学会  

    researchmap

  • 単一施設における節外性NK/T細胞リンパ腫、鼻腔(ENKL)における26例の後方視的解析 EBV-DNA定量の有用性

    山田 隆, 古山 悠里, 水戸部 正樹, 米沢 穂高, 鈴木 隆晴, 諏訪部 達也, 片桐 隆幸, 河本 啓介, 布施 香子, 柴崎 康彦, 増子 正義, 大島 孝一, 曽根 博仁, 瀧澤 淳

    日本血液学会学術集会   84回   294 - 294   2022.10

     More details

    Language:English   Publisher:(一社)日本血液学会  

    researchmap

  • WT1ペプチドワクチン投与後10年間以上にわたり持続するWT1特異的な細胞傷害性T細胞

    諏訪部 達也, 柴崎 康彦, 田村 秀, 片桐 隆幸, 井田 桃里, 布施 香子, 牛木 隆志, 曽根 博仁, 成田 美和子, 増子 正義

    日本血液学会学術集会   84回   117 - 117   2022.10

     More details

    Language:English   Publisher:(一社)日本血液学会  

    researchmap

  • 当科におけるIVLBCL22例の後方視的解析

    鈴木 隆晴, 水戸部 正樹, 武田 ルイ, 諏訪部 達也, 片桐 隆幸, 河本 啓介, 宮腰 淑子, 北嶋 俊樹, 小堺 貴司, 柴崎 康彦, 黒田 裕行, 棗田 学, 大島 孝一, 曽根 博仁, 瀧澤 淳

    日本血液学会学術集会   84回   557 - 557   2022.10

     More details

    Language:English   Publisher:(一社)日本血液学会  

    researchmap

  • 同種移植後day30の末梢血CD8TN、CD4TEM割合は急性GVHD発症のバイオマーカーとなる

    片桐 隆幸, 古山 悠里, 米沢 穂高, 諏訪部 達也, 布施 香子, 柴崎 康彦, 瀧澤 淳, 曽根 博仁, 増子 正義

    日本血液学会学術集会   84回   880 - 880   2022.10

     More details

    Language:English   Publisher:(一社)日本血液学会  

    researchmap

  • イノツズマブによる再寛解導入に引き続いてブリナツモマブを投与し再移植できたB-ALLの1例

    米澤 穂高, 布施 香子, 水戸部 正樹, 武田 るい, 諏訪部 達也, 片桐 隆幸, 柴崎 康彦, 瀧澤 淳, 成田 美和子, 曽根 博仁, 増子 正義

    臨床血液   62 ( 10 )   1526 - 1526   2021.10

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • ドナーリンパ球のコンドロイチン硫酸合成低下はGVHDを軽減する(Genetic manipulation resulting in decreased donor chondroitin sulfate mitigates GVHD in mice)

    田村 秀, 牛木 隆志, 諏訪部 達也, 片桐 隆幸, 石黒 創, 布施 香子, 柴崎 康彦, 進藤 岳郎, 五十嵐 道弘, 曽根 博仁, 増子 正義

    日本血液学会学術集会   83回   OS3 - 1   2021.9

     More details

    Language:English   Publisher:(一社)日本血液学会  

    researchmap

  • AMLにおける造血幹細胞移植後1年未満の再発は高い死亡率と相関する(Post-transplant relapse of AML within one year is associated with a high mortality rate)

    片桐 隆幸, 本宮 奈津子, 武田 ルイ, 水戸部 正樹, 米沢 穂高, 諏訪部 達也, 布施 香子, 柴崎 康彦, 瀧澤 淳, 曽根 博仁, 増子 正義

    日本血液学会学術集会   83回   PS - 10   2021.9

     More details

    Language:English   Publisher:(一社)日本血液学会  

    researchmap

  • WT1ペプチドワクチン投与後のCML患者におけるWT1特異的CTLの持続性と多様性(Persistence and diversity of WT1-specific CTLs in a CML patient vaccinated WT1 peptide)

    諏訪部 達也, 柴崎 康彦, 田村 秀, 片桐 隆幸, 布施 香子, 牛木 隆志, 曽根 博仁, 成田 美和子, 増子 正義

    日本血液学会学術集会   83回   PS - 1   2021.9

     More details

    Language:English   Publisher:(一社)日本血液学会  

    researchmap

  • Intensive oral care can reduce bloodstream infection with coagulase-negative staphylococci after neutrophil engraftment in allogeneic hematopoietic stem-cell transplantation

    Tatsuya Suwabe, Kyoko Fuse, Kouji Katsura, Marie Soga, Takayuki Katagiri, Yasuhiko Shibasaki, Miwako Narita, Hirohito Sone, Masayoshi Masuko

    Supportive Care in Cancer   30 ( 1 )   475 - 485   2021.7

     More details

    Publishing type:Research paper (scientific journal)   Publisher:Springer Science and Business Media LLC  

    DOI: 10.1007/s00520-021-06447-8

    researchmap

    Other Link: https://link.springer.com/article/10.1007/s00520-021-06447-8/fulltext.html

  • 陰茎・陰嚢病変を合併した精巣原発DLBCL

    水戸部 正樹, 武田 ルイ, 米沢 穂高, 田村 秀, 諏訪部 達也, 片桐 隆幸, 河本 啓介, 布施 香子, 柴崎 康彦, 増子 正義, 井上 佳菜子, 三好 寛明, 大島 孝一, 曽根 博仁, 瀧澤 淳

    臨床血液   62 ( 6 )   668 - 668   2021.6

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • 同種造血幹細胞移植後の慢性GVHDとしての類上皮肉芽腫および多発筋炎

    諏訪部 達也, 布施 香子, 水戸部 正樹, 武田 ルイ, 米沢 穂高, 片桐 隆幸, 河本 啓介, 牛木 隆志, 柴崎 康彦, 瀧澤 淳, 成田 美和子, 曽根 博仁, 大島 孝一, 増子 正義

    臨床血液   62 ( 6 )   675 - 675   2021.6

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • WT1-specific CD8 + cytotoxic T cells with the capacity for antigen-specific expansion accumulate in the bone marrow in MDS.

    Tatsuya Suwabe, Yasuhiko Shibasaki, Hiroyuki Sato, Suguru Tamura, Takayuki Katagiri, Hiroki Nemoto, Takuya Kasami, Takashi Kozakai, Ayako Nanba, Toshiki Kitajima, Kyoko Fuse, Takashi Ushiki, Hirohito Sone, Miwako Narita, Masayoshi Masuko

    International journal of hematology   113 ( 5 )   723 - 734   2021.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Wilms' tumor 1 (WT1) is a tumor-associated antigen and immunotherapy target in myelodysplastic syndrome (MDS). Further information is needed on the characteristics of WT1-specific CD8 + T cells to develop immunotherapeutic strategies for MDS. To clarify the frequency, distribution, and phenotype of WT1-specific CD8 + T cells, which occur innately in MDS patients, we analyzed paired peripheral blood (PB) and bone marrow (BM) samples from 39 patients with MDS or acute myeloid leukemia with myelodysplasia-related changes. The median frequency of WT1 tetramer-binding CD8 + T cells in the CD8 + T cell population was 0.11% in PB and 0.18% in BM. A further tetramer assay combined with mixed lymphocyte peptide culture (MLPC assay) was used to detect functional WT1-specific CD8 + T cells that could respond to the WT1 peptide. Functional WT1-specific CD8 + T cells were detected in BM in 61% of patients, which was significantly higher than in PB (23%, p = 0.001). The frequency of these cells estimated by the MLPC assay was tenfold higher in BM than in PB. The majority of WT1 tetramer-binding CD8 + T cells in BM had a unique phenotype with co-expression of CD39 and CXCR4. These findings will facilitate the development of novel immunotherapeutic strategies for MDS.

    DOI: 10.1007/s12185-021-03083-0

    PubMed

    researchmap

  • GB療法施行中にHigh-grade B-cell lymphoma with MYC and BCL2 rearrangementsで再燃したFollicular lymphoma(Grade 3A)の2症例

    水戸部 正樹, 本宮 奈津子, 武田 ルイ, 米沢 穂高, 鈴木 隆晴, 諏訪部 達也, 片桐 隆幸, 河本 啓介, 布施 香子, 柴崎 康彦, 増子 正義, 井上 佳菜子, 三好 寛明, 大島 孝一, 曽根 博仁, 瀧澤 淳

    日本リンパ網内系学会会誌   61   114 - 114   2021.5

     More details

    Language:Japanese   Publisher:(一社)日本リンパ網内系学会  

    researchmap

  • 腎障害を有する高悪性度B細胞リンパ腫症例にDA-EPOCH-Rを施行した1例

    水戸部 正樹, 河本 啓介, 鈴木 隆晴, 米沢 穂高, 田村 秀, 諏訪部 達也, 根本 洋樹, 布施 香子, 柴崎 康彦, 増子 正義, 三好 寛明, 大島 孝一, 曽根 博仁, 瀧澤 淳

    臨床血液   62 ( 5 )   532 - 532   2021.5

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • ルキソルチニブ・ヒドロキシウレア併用療法が奏効した慢性好中球性白血病(CNL)の1例

    武田 ルイ, 布施 香子, 片桐 隆幸, 河本 啓介, 柴崎 康彦, 瀧澤 淳, 成田 美和子, 野本 信彦, 曽根 博仁, 増子 正義

    臨床血液   62 ( 5 )   529 - 530   2021.5

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • A multicenter phase II study of intrabone single-unit cord blood transplantation without antithymocyte globulin. International journal

    Tetsuya Nishida, Takeshi Kobayashi, Masashi Sawa, Shinichi Masuda, Yasuhiko Shibasaki, Tatsunori Goto, Noriko Fukuhara, Nobuharu Fujii, Kazuhiro Ikegame, Junichi Sugita, Takashi Ikeda, Yachiyo Kuwatsuka, Ritsuro Suzuki, Yuho Najima, Noriko Doki, Tomonori Kato, Yuichiro Inagaki, Yoshikazu Utsu, Nobuyuki Aotsuka, Masayoshi Masuko, Seitaro Terakura, Yasushi Onishi, Yoshinobu Maeda, Masaya Okada, Takanori Teshima, Makoto Murata

    Annals of hematology   100 ( 3 )   743 - 752   2021.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    To overcome the delayed or failed engraftment after unrelated cord blood transplantation (CBT), we conducted a multicenter phase II study of intrabone single-unit CBT without antithymocyte globulin (ATG) for adult patients with hematological malignancies (UMIN-CTR, UMIN000020997). Sixty-four patients received an intrabone injection of unwashed (n = 61) or washed (n = 3) cord blood after local anesthesia. All injection-related adverse events were mild and resolved spontaneously. Sixty-two patients were evaluable for the efficacy of intrabone CBT of serological HLA-A, -B, and -DR ≥ 4/6 matched cord blood with a median number of 2.57 × 107/kg cryopreserved total nucleated cells. The probability of survival with neutrophil engraftment on day 28 was 77.4% (95% confidence interval, 67.0-85.8%), which exceeded the threshold value. The cumulative incidences of neutrophils ≥ 0.5 × 109/L on day 60 was 80.6% (68.2-88.6%), with a median time to recovery of 21 days after transplantation. The cumulative incidences of platelets ≥ 20 × 109/L and platelets ≥ 50 × 109/L on day 100 were 75.8% (62.6-84.9%) and 72.6% (59.4-82.1%), respectively, with median time to platelets ≥ 20 × 109/L and platelets ≥ 50 × 109/L of 38 and 45 days after transplantation, respectively. The cumulative incidences of grade II-IV and III-IV acute graft-versus-host disease were 29.0% and 6.5%, respectively. All responded to steroid therapy, and secondary treatments were not required. The present study suggests the efficacy of intrabone single-unit CBT without ATG in terms of early engraftment and controllable acute graft-versus-host disease.

    DOI: 10.1007/s00277-020-04365-z

    PubMed

    researchmap

  • DA-EPOCH-R therapy for high-grade B-cell lymphoma with <i>MYC</i> and <i>BCL2</i> and/or <i>BCL6</i> rearrangements in a patient with renal dysfunction

    Masaki Mitobe, Keisuke Kawamoto, Takaharu Suzuki, Tatsuya Suwabe, Yasuhiko Shibasaki, Masayoshi Masuko, Kanako Inoue, Hiroaki Miyoshi, Koichi Ohshima, Hirohito Sone, Jun Takizawa

    Journal of Clinical and Experimental Hematopathology   61 ( 1 )   42 - 47   2021

     More details

    Publishing type:Research paper (scientific journal)   Publisher:Japanese Society for Lymphoreticular Tissue Research  

    DOI: 10.3960/jslrt.20043

    researchmap

  • Marker chromosome is a strong poor prognosis factor after allogeneic HSCT for adverse-risk AML patients. International journal

    Kyoko Fuse, Tomoyuki Tanaka, Yasuhiko Shibasaki, Tatsuo Furukawa, Miwako Narita, Hirohito Sone, Masayoshi Masuko

    European journal of haematology   105 ( 5 )   616 - 625   2020.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    INTRODUCTION: Chromosome analysis is necessary for the risk classification of acute myeloid leukemia (AML). Marker chromosome (MC) is a fragmented chromosome whose origin cannot be identified from other chromosomes and originates from marked genomic instability. Although AML with MC (MC+) has a poor prognosis even after intensive chemotherapy, its influence on the outcome after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is unclear. OBJECTIVE AND METHODS: We retrospectively analyzed 162 AML patients after allo-HSCT. To evaluate the significance of MC, we compared it with other chromosomal abnormalities. RESULT: Marker chromosome was detected in 14 (8.6%, MC+) patients (vs MC-, n = 158). The 2-year overall survival (OS) in MC+ vs MC- was 26.8% vs 62.2% (P = .0098). The 2-year cumulative incidence of relapse (CIR) in MC+ vs MC- was 80.4% vs 35.5% (P = .0004). Among adverse-risk AML (AD-AML, n = 36), AD-AML/MC+ (n = 11) demonstrated a poorer 2-year OS (9.1%, vs AD-AML/MC- n = 25, 58.3%, P = .0031) and higher 2-year CIR (89.6%, vs AD-AML/MC- 44.7%, P = .002). In multivariate analysis, MC (HR 3.08, 95% CI; 1.02-9.29, P = .046) and HCT-CI (HR 3.23, 95% CI; 1.00-10.4, P = .049) were independent risk factors for CIR among AD-AML. CONCLUSION: Our study suggests MC as a new independent factor for chromosome risk classification to further classify AD-AML.

    DOI: 10.1111/ejh.13495

    PubMed

    researchmap

  • Hypereosinophilia-related liver pseudotumor with elevated interleukin-5 levels preceding T-cell lymphoma. International journal

    Atsunori Tsuchiya, Tomoyuki Tanaka, Yasuhiko Shibasaki, Shuji Terai

    JGH open : an open access journal of gastroenterology and hepatology   4 ( 2 )   312 - 314   2020.4

     More details

    Language:English  

    A 61-year-old woman with hypereosinophilia and elevated interleukin (IL)-5 level was admitted to our hospital after detection of multiple liver tumors. Liver biopsy demonstrated that the tumor consisted of scar tissue with remnants of eosinophilic infiltration, suggesting that it had formed by massive eosinophilic infiltration. The hypereosinophilia was treated mainly by prednisolone, and thereafter, the liver tumors disappeared. However, 10 months postadmission, CD4+ T-cell lymphoma, which can produce IL-5, was detected in the nasopharynx and oropharynx. Therefore, we believe that this is a rare case of hypereosinophilia-related liver pseudotumor induced by presumed by IL-5 elevation.

    DOI: 10.1002/jgh3.12253

    PubMed

    researchmap

  • The Glasgow prognostic score divides high-risk hematopoietic cell transplantation-specific comorbidity index patients into stratified subgroups in allogeneic hematopoietic cell transplantation. International journal

    Yasuhiko Shibasaki, Tatsuya Suwabe, Takayuki Katagiri, Kyoko Fuse, Miwako Narita, Hirohito Sone, Masayoshi Masuko

    Annals of hematology   99 ( 3 )   671 - 673   2020.3

     More details

  • Using a machine learning algorithm to predict acute graft-versus-host disease following allogeneic transplantation. Reviewed International journal

    Yasuyuki Arai, Tadakazu Kondo, Kyoko Fuse, Yasuhiko Shibasaki, Masayoshi Masuko, Junichi Sugita, Takanori Teshima, Naoyuki Uchida, Takahiro Fukuda, Kazuhiko Kakihana, Yukiyasu Ozawa, Tetsuya Eto, Masatsugu Tanaka, Kazuhiro Ikegame, Takehiko Mori, Koji Iwato, Tatsuo Ichinohe, Yoshinobu Kanda, Yoshiko Atsuta

    Blood advances   3 ( 22 )   3626 - 3634   2019.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Acute graft-versus-host disease (aGVHD) is 1 of the critical complications that often occurs following allogeneic hematopoietic stem cell transplantation (HSCT). Thus far, various types of prediction scores have been created using statistical calculations. The primary objective of this study was to establish and validate the machine learning-dependent index for predicting aGVHD. This was a retrospective cohort study that involved analyzing databases of adult HSCT patients in Japan. The alternating decision tree (ADTree) machine learning algorithm was applied to develop models using the training cohort (70%). The ADTree algorithm was confirmed using the hazard model on data from the validation cohort (30%). Data from 26 695 HSCT patients transplanted from allogeneic donors between 1992 and 2016 were included in this study. The cumulative incidence of aGVHD was 42.8%. Of >40 variables considered, 15 were adapted into a model for aGVHD prediction. The model was tested in the validation cohort, and the incidence of aGVHD was clearly stratified according to the categorized ADTree scores; the cumulative incidence of aGVHD was 29.0% for low risk and 58.7% for high risk (hazard ratio, 2.57). Predicting scores for aGVHD also demonstrated the link between the risk of development aGVHD and overall survival after HSCT. The machine learning algorithms produced clinically reasonable and robust risk stratification scores. The relatively high reproducibility and low impacts from the interactions among the variables indicate that the ADTree algorithm, along with the other data-mining approaches, may provide tools for establishing risk score.

    DOI: 10.1182/bloodadvances.2019000934

    PubMed

    researchmap

  • Patient-based prediction algorithm of relapse after allo-HSCT for acute Leukemia and its usefulness in the decision-making process using a machine learning approach. Reviewed International journal

    Kyoko Fuse, Shun Uemura, Suguru Tamura, Tatsuya Suwabe, Takayuki Katagiri, Tomoyuki Tanaka, Takashi Ushiki, Yasuhiko Shibasaki, Naoko Sato, Toshio Yano, Takashi Kuroha, Shigeo Hashimoto, Tatsuo Furukawa, Miwako Narita, Hirohito Sone, Masayoshi Masuko

    Cancer medicine   8 ( 11 )   5058 - 5067   2019.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Although allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative therapy for high-risk acute leukemia (AL), some patients still relapse. Since patients simultaneously have many prognostic factors, difficulties are associated with the construction of a patient-based prediction algorithm of relapse. The alternating decision tree (ADTree) is a successful classification method that combines decision trees with the predictive accuracy of boosting. It is a component of machine learning (ML) and has the capacity to simultaneously analyze multiple factors. Using ADTree, we attempted to construct a prediction model of leukemia relapse within 1 year of transplantation. With the model of training data (n = 148), prediction accuracy, the AUC of ROC, and the κ-statistic value were 78.4%, 0.746, and 0.508, respectively. The false positive rate (FPR) of the relapse prediction was as low as 0.134. In an evaluation of the model with validation data (n = 69), prediction accuracy, AUC, and FPR of the relapse prediction were similar at 71.0%, 0.667, and 0.216, respectively. These results suggest that the model is generalized and highly accurate. Furthermore, the output of ADTree may visualize the branch point of treatment. For example, the selection of donor types resulted in different relapse predictions. Therefore, clinicians may change treatment options by referring to the model, thereby improving outcomes. The present results indicate that ML, such as ADTree, will contribute to the decision-making process in the diversified allo-HSCT field and be useful for preventing the relapse of leukemia.

    DOI: 10.1002/cam4.2401

    PubMed

    researchmap

  • Myeloablative and reduced-intensity conditioning in HLA-haploidentical peripheral blood stem cell transplantation using post-transplant cyclophosphamide. Reviewed International journal

    Junichi Sugita, Yusuke Kagaya, Toshihiro Miyamoto, Yasuhiko Shibasaki, Koji Nagafuji, Shuichi Ota, Tatsuo Furukawa, Miho Nara, Koichi Akashi, Shuichi Taniguchi, Mine Harada, Keitaro Matsuo, Takanori Teshima

    Bone marrow transplantation   54 ( 3 )   432 - 441   2019.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    We conducted two parallel prospective, multicenter, phase II studies to evaluate the safety and efficacy of HLA-haploidentical peripheral blood stem cell transplantation using post-transplant cyclophosphamide (PTCy-haploPBSCT) following myeloablative conditioning (MAC, n = 50) and reduced-intensity conditioning (RIC, n = 77). Event-free survival (EFS) at 1-year as for primary endpoint was 64% and 43% in the MAC and RIC groups, respectively. Neutrophil engraftment was achieved in 98% and 94% in the MAC and RIC groups, respectively. The incidences of grades II-IV and III-IV acute graft-versus-host disease (GVHD) were 18% and 8% in the MAC group, and 14% and 5% in the RIC group, respectively. Those of all grade and moderate to severe chronic GVHD at 2-year were 36% and 20% in the MAC group, and 27% and 20% in the RIC group, respectively. Overall survival (OS), EFS, nonrelapse mortality, and relapse rate at 2-year were 68%, 54%, 10%, and 36% in the MAC group, and 44%, 35%, 20%, and 45% in the RIC group, respectively. Notably, 83% and 86% of patients who survived without relapse stopped immunosuppressant at 2-year in the MAC and RIC groups, respectively. Our results indicate that both MAC and RIC are valid options for PTCy-haploPBSCT for adults with hematological malignancies.

    DOI: 10.1038/s41409-018-0279-1

    PubMed

    researchmap

  • Gemcitabine, Dexamethasone, and Cisplatin Regimen as an Effective Salvage Therapy for High-grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements. Reviewed

    Masaki Mitobe, Keisuke Kawamoto, Takaharu Suzuki, Maiko Kiryu, Suguru Tamura, Ayako Nanba, Tatsuya Suwabe, Tomoyuki Tanaka, Kyoko Fuse, Yasuhiko Shibasaki, Masayoshi Masuko, Hiroaki Miyoshi, Koichi Ohshima, Hirohito Sone, Jun Takizawa

    Internal medicine (Tokyo, Japan)   58 ( 4 )   575 - 580   2019.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    A 61-year-old woman exhibited right inguinal lymphadenopathy and right lower limb edema approximately 1 month prior to hospitalization. She was diagnosed with high grade B-cell lymphoma, and a lymph node biopsy and fluorescence in situ hybridization indicated MYC, BCL2, and BCL6 rearrangements (triple-hit lymphoma). She had progressive disease that was CD20-negative after two courses of rituximab, cyclophosphamide, doxorubicin, vincristine, methotrexate/ifosfamide, etoposide, high-dose cytarabine (R-CODOX-M/IVAC) therapy. Subsequent etoposide, prednisolone, vincristine, cyclophosphamide, doxorubicin (EPOCH) therapy was not effective. However, after two cycles of gemcitabine, dexamethasone, and cisplatin (GDP) therapy, she achieved a complete response and was able to undergo autologous peripheral blood stem cell transplantation. GDP therapy may be effective as salvage therapy for chemotherapy-resistant triple-hit lymphoma.

    DOI: 10.2169/internalmedicine.1686-18

    PubMed

    researchmap

  • Anaplastic large cell lymphoma, with 1,25(OH) 2 D 3 -mediated hypercalcemia: A case report. Reviewed

    Masaki Mitobe, Keisuke Kawamoto, Takaharu Suzuki, Maiko Kiryu, Ayako Nanba, Tatsuya Suwabe, Tomoyuki Tanaka, Kyoko Fuse, Yasuhiko Shibasaki, Masayoshi Masuko, Hiroaki Miyoshi, Koichi Ohshima, Hirohito Sone, Jun Takizawa

    Journal of clinical and experimental hematopathology : JCEH   59 ( 1 )   22 - 28   2019

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Hypercalcemia due to malignant tumors including malignant lymphomas is relatively common. Among cancer patients with hypercalcemia, humoral hypercalcemia of malignancy is the most common and accounts for about 80% of all cases with hypercalcemia. 1,25-dihydroxyvitamin D
    3
    (1,25(OH)
    2
    D
    3
    )-mediated hypercalcemia is relatively rare. Although malignant lymphoma has been also reported to cause 1,25(OH)
    2
    D
    3
    -mediated hypercalcemia, it is not known whether there is any association between 1,25(OH)
    2
    D
    3
    -mediated hypercalcemia and any specific histological type of malignant lymphoma. We herein report a case of an anaplastic large cell lymphoma (ALCL), anaplastic lymphoma kinase (ALK) -negative with 1,25(OH)
    2
    D
    3
    -mediated hypercalcemia, which has never been previously reported. An 80-year-old Japanese man was admitted to our department due to acute exacerbation of hypercalcemia. He was diagnosed with ALCL, ALK-negative. Serum 1,25(OH)
    2
    D
    3
    level was high and seemed to be associated with the lymphoma because the serum calcium and 1,25(OH)
    2
    D
    3
    levels improved in response to chemotherapy. Histological findings showed that many CD68 positive macrophages were observed in the microenvironment of tumor cells. Lymphoma cells or tumor microenvironmental cells may produce 1,25(OH)
    2
    D
    3
    because several previous reports showed the source of 1,25(OH)
    2
    D
    3
    can be either lymphoma or tumor microenvironmental cells. Moreover, because 1,25(OH)
    2
    D
    3
    -mediated hypercalcemia has been reported regardless of the specific histological type of lymphoma, tumor microenvironmental cells may be involved in this condition. However, we could not identify the source of 1,25(OH)
    2
    D
    3
    in this case. The association between 1,25(OH)
    2
    D
    3
    production and prognosis in malignant lymphomas is yet unknown; further studies are needed to elucidate the clinical characteristics of malignant lymphoma with 1,25(OH)
    2
    D
    3
    -mediated hypercalcemia.

    DOI: 10.3960/jslrt.18033

    PubMed

    researchmap

  • Cladribine treatment for Erdheim-Chester disease involving the central nervous system and concomitant polycythemia vera: A case report. Reviewed

    Suguru Tamura, Keisuke Kawamoto, Hiroaki Miyoshi, Takaharu Suzuki, Takayuki Katagiri, Takuya Kasami, Hiroki Nemoto, Shukuko Miyakoshi, Hironori Kobayashi, Yasuhiko Shibasaki, Masayoshi Masuko, Kengo Takeuchi, Koichi Ohshima, Hirohito Sone, Jun Takizawa

    Journal of clinical and experimental hematopathology : JCEH   58 ( 4 )   161 - 165   2018.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Erdheim-Chester disease (ECD), a rare form of non-Langerhans cell histiocytosis, is characterized by the infiltration of foamy CD68+ and CD1a- histiocytes into multiple organ systems. Central nervous system (CNS) involvement has recently been reported to be a poor prognostic factor when treating ECD with interferon alpha. We report the case of a 66-year-old Japanese patient with ECD involving the CNS who harbored the BRAF V600E mutation and also concomitantly developed polycythemia vera with the JAK2 V617F mutation. We confirmed 2-chlorodeoxyadenosine (cladribine) therapy to be effective for the patient in this case.

    DOI: 10.3960/jslrt.18015

    PubMed

    researchmap

  • Refinement of the Glasgow Prognostic Score as a pre-transplant risk assessment for allogeneic hematopoietic cell transplantation. Reviewed

    Yasuhiko Shibasaki, Tatsuya Suwabe, Takayuki Katagiri, Tomoyuki Tanaka, Takashi Ushiki, Kyoko Fuse, Naoko Sato, Toshio Yano, Takashi Kuroha, Shigeo Hashimoto, Miwako Narita, Tatsuo Furukawa, Hirohito Sone, Masayoshi Masuko

    International journal of hematology   108 ( 3 )   282 - 289   2018.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Springer Tokyo  

    The Hematopoietic Cell Transplantation-specific Comorbidity Index (HCT-CI) is a widely used tool for pre-transplant risk assessment. Allogeneic hematopoietic cell transplantation (HCT) is performed on patients with diverse backgrounds, highlighting the need for other predictors to complement the HCT-CI and support bedside decision-making. There is a strong body of evidence supporting the use of pre-transplant serum ferritin (SF) in risk assessments of allogeneic HCT. We additionally found that the Glasgow Prognostic Score (GPS), which assesses inflammatory biomarkers and predicts survival of patients with solid organ malignancies, is a useful predictive marker for overall survival (OS) and non-relapse mortality (NRM) in allogeneic HCT, independent of HCT-CI and SF. In this study, we refined the GPS by adding pre-transplant SF to improve its prognostic ability and enable better stratification; we call this revised index the HCT-specific revised Glasgow Prognostic Score (HCT-GPS). We observed that the HCT-GPS more accurately predicted NRM and early-term OS than the GPS. Moreover, the HCT-GPS provides an independent prognostic factor adjusted for the HCT-CI and disease status, and stratifies patients into four risk groups by OS and NRM. Thus, the HCT-GPS is a useful index for predicting early-term complications after allogeneic HCT in patients with hematopoietic diseases.

    DOI: 10.1007/s12185-018-2463-x

    Scopus

    PubMed

    researchmap

  • Heterogeneity of intrahepatic iron deposition in transfusion-dependent iron overload patients with hematological malignancies. Reviewed International journal

    Hironori Kobayashi, Norihiko Yoshimura, Shun Uemura, Takayuki Katagiri, Tomoyuki Tanaka, Takashi Ushiki, Kyoko Fuse, Yasuhiko Shibasaki, Miwako Narita, Hirohito Sone, Masayoshi Masuko

    Leukemia research   70   41 - 44   2018.7

     More details

    Language:English   Publisher:Elsevier Ltd  

    DOI: 10.1016/j.leukres.2018.05.005

    Scopus

    PubMed

    researchmap

  • Effects of Prophylactic Foscarnet on Human Herpesvirus-6 Reactivation and Encephalitis in Cord Blood Transplant Recipients: A Prospective Multicenter Trial with an Historical Control Group. Reviewed International journal

    Masao Ogata, Kuniko Takano, Yukiyoshi Moriuchi, Tadakazu Kondo, Toshimitsu Ueki, Nobuaki Nakano, Takehiko Mori, Nobuhiko Uoshima, Koji Nagafuji, Satoshi Yamasaki, Yasuhiko Shibasaki, Rika Sakai, Koji Kato, Ilseung Choi, Yumi Jo, Tetsuya Eto, Shinichi Kako, Kumi Oshima, Takahiro Fukuda

    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation   24 ( 6 )   1264 - 1273   2018.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Elsevier Inc.  

    Cord blood transplantation (CBT) is a distinct risk factor for human herpesvirus-6 (HHV-6) reactivation and HHV-6 encephalitis. In a prospective multicenter trial we investigated the effects of prophylactic foscarnet (90 mg/kg i.v. infusion from days 7 to 27 after CBT) on the occurrence of HHV-6 reactivation, HHV-6 encephalitis, and acute graft-versus-host disease (aGVHD) in CBT recipients. Between 2014 and 2016, 57 patients were included in a foscarnet-prophylaxis group. Outcomes were compared with an historical control group who received CBT between 2010 and 2014 (standard-treatment group, n = 63). The cumulative incidence of high-level HHV-6 reactivation, defined as plasma HHV-6 DNA ≥ 104 copies/mL, at 60 days after CBT was significantly lower in the foscarnet-prophylaxis group than in the standard-treatment group (18.3% versus 57.3%, P < .001). Multivariate analysis revealed that myeloablative preconditioning and standard treatment were significant risk factors for high-level HHV-6 reactivation. The cumulative incidence of HHV-6 encephalitis at 60 days after CBT was not different between the groups (foscarnet-prophylaxis group, 12.4%; standard-treatment group, 4.9%; P = .14). The cumulative incidences of grades II to IV and grades III to IV aGVHD at 60 days after CBT were not different between the groups (grades II to IV aGVHD: foscarnet-prophylaxis group, 42.0%; standard-treatment group, 40.5%; P = .96; grades III to IV aGVHD: foscarnet-prophylaxis group, 14.5%; standard-treatment group, 14.5%; P = 1.00). In the setting of this study foscarnet significantly suppressed systemic HHV-6 reactivation in CBT recipients but failed to prevent the development of HHV-6 encephalitis. Suppression of HHV-6 reactivation by foscarnet did not show any effects against the incidence of aGVHD.

    DOI: 10.1016/j.bbmt.2018.02.008

    Scopus

    PubMed

    researchmap

  • The Glasgow Prognostic Score as a pre-transplant risk assessment for allogeneic hematopoietic cell transplantation. Reviewed International journal

    Yasuhiko Shibasaki, Tatsuya Suwabe, Takayuki Katagiri, Tomoyuki Tanaka, Hironori Kobayashi, Kyoko Fuse, Takashi Ushiki, Naoko Sato, Toshio Yano, Takashi Kuroha, Shigeo Hashimoto, Miwako Narita, Tatsuo Furukawa, Hirohito Sone, Masayoshi Masuko

    Clinical transplantation   31 ( 11 )   2017.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:WILEY  

    Evaluation methods, such as scoring systems for predicting complications in advance, are necessary for determining the adaptation of allogeneic hematopoietic cell transplantation (HCT) and selecting appropriate conditioning regimens. The Hematopoietic Cell Transplantation-specific Comorbidity Index (HCT-CI), which is based on functions of main organs, is a useful tool for pre-transplant risk assessments and has been widely applied in determining treatment strategies for patients with hematological diseases. However, as allogeneic HCT is performed on patients with diverse backgrounds, another factor, which reinforces the HCT-CI, is required to evaluate pre-transplant risk assessments. The Glasgow Prognostic Score (GPS), which assesses the combined C-reactive protein and albumin, was reported to predict survival of patients with solid-organ malignancies independently of receiving chemo/radiotherapy and stages of cancer. In this study, we applied the GPS for pre-transplant risk assessments for allogeneic HCT. The GPS successfully stratified the patients into three risk groups of overall survival (OS) and non-relapse mortality (NRM). Moreover, the GPS could predict outcomes independently of the HCT-CI for OS and NRM in multivariate analysis. The GPS is considered to be a useful tool and reinforces the HCT-CI for determining adaptation of allogeneic HCT for patients with hematopoietic neoplasms.

    DOI: 10.1111/ctr.13103

    Web of Science

    PubMed

    researchmap

  • Successful 5-azacytidine treatment of myeloid sarcoma and leukemia cutis associated with myelodysplastic syndrome: A case report and literature review. Reviewed International journal

    Takayuki Katagiri, Takashi Ushiki, Masayoshi Masuko, Tomoyuki Tanaka, Shukuko Miyakoshi, Kyoko Fuse, Yasuhiko Shibasaki, Jun Takizawa, Sadao Aoki, Hirohito Sone

    Medicine   96 ( 36 )   e7975   2017.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:LIPPINCOTT WILLIAMS & WILKINS  

    RATIONALE: Myeloid sarcoma (MS) and leukemia cutis (LC) are extramedullary tumors comprising myeloid blasts. They can occur de novo or concurrently with hematological disorders, usually acute myeloid leukemia (AML). AML chemotherapy is generally the initial therapy for MS and LC, and hematopoietic stem cell transplantation (HSCT) can be considered as additional therapy. However, treatment for older patients who are unable to continue intensive chemotherapy is not currently standardized. PATIENT CONCERNS: A 71-year-old Japanese woman was diagnosed with multiple MSs associated with myelodysplastic syndrome (MDS), using bone marrow aspiration and lymph node biopsy. DIAGNOSES: Additionally, LC was diagnosed by skin biopsy. Extramedullary MS and LC lesions were formed by massive infiltration of myeloblastic cells. INTERVENTIONS: Twenty courses of 5-azacytidine (5-Aza) were administrated as maintenance therapy after induction therapy with daunorubicin and cytarabine. OUTCOMES: Myeloblasts decreased in the bone marrow and the LC disappeared after induction therapy. The MSs completely disappeared, except for the palatine tonsil lesion, after 5-Aza maintenance therapy. 5-Aza treatment provided long-term partial response for more than 21 months. LESSONS: 5-Aza was well tolerated and may be a good option for the treatment of MS and LC associated with MDS, especially in older patients who cannot receive HSCT.

    DOI: 10.1097/MD.0000000000007975

    Web of Science

    PubMed

    researchmap

  • 移植前予後予測モデルとしての同種造血細胞移植特異的Glasgow Prognostic Score(HCT specific Glasgow Prognostic Score as a new predictive tool for pre-transplant risk assessments)

    Shibasaki Yasuhiko, Suwabe Tatsuya, Katagiri Takayuki, Tanaka Tomoyuki, Kobayashi Hironori, Fuse Kyoko, Ushiki Takashi, Narita Miwako, Sone Hirohito, Masuko Masayoshi

    臨床血液   58 ( 9 )   1547 - 1547   2017.9

     More details

    Language:English   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • Phase II study of intrabone single unit cord blood transplantation for hematological malignancies. Reviewed International journal

    Makoto Murata, Yoshinobu Maeda, Masayoshi Masuko, Yasushi Onishi, Tomoyuki Endo, Seitaro Terakura, Yuichi Ishikawa, Chisako Iriyama, Yoko Ushijima, Tatsunori Goto, Nobuharu Fujii, Mitsune Tanimoto, Hironori Kobayashi, Yasuhiko Shibasaki, Noriko Fukuhara, Yoshihiro Inamoto, Ritsuro Suzuki, Yoshihisa Kodera, Tadashi Matsushita, Hitoshi Kiyoi, Tomoki Naoe, Tetsuya Nishida

    Cancer science   108 ( 8 )   1634 - 1639   2017.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    The outcomes of cord blood transplantation with non-irradiated reduced-intensity conditioning for hematological malignancies need to be improved because of graft failure and delayed engraftment. Intrabone infusion of cord blood cells has the potential to resolve the problems. In this phase II study, 21 adult patients with hematological malignancy received intrabone transplantation of serological HLA-A, B, and DR ≥4/6 matched single cord blood with a median number of cryopreserved total nucleated cells of 2.7 × 107 /kg (range, 2.0-4.9 × 107 /kg) following non-irradiated fludarabine-based reduced-intensity conditioning. Short-term methotrexate and tacrolimus were given as graft-versus-host disease prophylaxis, and granulocyte colony-stimulating factor was given after transplantation. No severe adverse events related to intrabone injection were observed. The cumulative incidences of neutrophils ≥0.5 × 109 /L, reticulocytes ≥1%, and platelets ≥20 × 109 /L recoveries were 76.2%, 71.4%, and 76.2%, respectively, with median time to recoveries of 17, 28, and 32 days after transplantation, respectively. The probability of survival with neutrophil engraftment on day 60 was 71.4%, and overall survival at 1 year after transplantation was 52.4%. The incidences of grade II-IV and III-IV acute graft-versus-host disease were 44% and 19%, respectively, with no cases of chronic graft-versus-host disease. The present study showed the safety of direct intrabone infusion of cord blood. Further analysis is required to confirm the efficacy of intrabone single cord blood transplantation with non-irradiated reduced-intensity conditioning for adult patients with hematological malignancy. This study was registered with UMIN-CTR, number 000000865.

    DOI: 10.1111/cas.13291

    PubMed

    researchmap

  • Donor Killer Immunoglobulin-Like Receptor Haplotype B/x Induces Severe Acute Graft-versus-Host Disease in the Presence of Human Leukocyte Antigen Mismatch in T Cell-Replete Hematopoietic Cell Transplantation. Reviewed International journal

    Ryosuke Hosokai, Masayoshi Masuko, Yasuhiko Shibasaki, Akihiko Saitoh, Tatsuo Furukawa, Chihaya Imai

    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation   23 ( 4 )   606 - 611   2017.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:ELSEVIER SCIENCE INC  

    Natural killer cells have been identified as a mediator of alloimmune reactions in allogeneic hematopoietic stem cell transplantation (HSCT). Killer immunoglobulin-like receptors (KIRs) are an important determinant of natural killer cell function. The relationship between KIR genotypes/haplotypes and clinical outcomes of allogeneic HSCT is complex and inconsistent among several reports. We assessed the clinical impact of KIR haplotype on T cell-replete allogeneic HSCTs performed in a single Japanese center for hematological malignancies (n = 106). A comparison of 2 groups, donor haplotypes A/A and B/x, revealed no significant differences in overall survival, relapse, and nonrelapse mortality. However, grade III to IV acute graft-versus-host disease (GVHD) occurred significantly more frequently in the KIR haplotype B/x group (A/A versus B/x: 4.9% versus 20.0%; P = .02). This was even more evident when HLA mismatch was present. The highest incidences of grade II to IV and grade III to IV acute GVHD were observed in patients who received allografts from HLA-mismatched donors with KIR haplotype B/x. These data highlight the importance of KIR genotyping in donor matching, especially when HLA mismatch allogeneic grafting is planned.

    DOI: 10.1016/j.bbmt.2016.12.638

    Web of Science

    PubMed

    researchmap

  • Successful umbilical cord blood hematopoietic stem cell transplantation in a patient with adult T-cell leukemia/lymphoma initially achieving complete remission with anti-CC chemokine receptor 4 antibody combined chemotherapy Reviewed

    SUWABE Tatsuya, TAKIZAWA Jun, NARITA Miwako, SONE Hirohito, MASUKO Masayoshi, SHIBASAKI Yasuhiko, KAIHATSU Akane, KATAGIRI Takayuki, MIYAKOSHI Shukuko, FUSE Kyoko, KOBAYASHI Hironori, USHIKI Takashi, MORIYAMA Masato

    Rinsho Ketsueki   58 ( 1 )   32 - 36   2017

     More details

    Language:Japanese   Publisher:The Japanese Society of Hematology  

    <p>A 62-year-old man with CHOP refractory adult T-cell leukemia/lymphoma (ATLL) received anti-CC chemokine receptor 4 antibody (mogamulizumab) combined with CHOP and achieved complete remission. At 71 days after the final administration of mogamulizumab, he received umbilical cord blood transplantation (CBT) using reduced intensity conditioning. Umbilical cord blood engraftment was confirmed on day16. Grade II acute graft-versus-host disease (GVHD) was diagnosed on day60 and was controlled by administration of methylprednisolone. There was no evidence of relapse at 9 months after CBT. Ratios of regulatory T cells in CD4 positive T cells were remarkably low during all of these periods. Since mogamulizumab reduces regulatory T cells, the frequency and severity of acute GVHD were reported to be increased in patients administered mogamulizumab before allogenic stem cell transplantation. Further experiences are needed for selecting optimal donor sources, the portability period and GVHD prophylaxis for patients using mogamulizumab before allogeneic stem cell transplantation.</p>

    DOI: 10.11406/rinketsu.58.32

    PubMed

    CiNii Article

    CiNii Books

    researchmap

  • 輸血依存患者における肝臓内鉄含有量を評価するための二重エネルギーCTの重要性(Significance of dual-energy CT to evaluate liver iron content in transfusion-dependent patients)

    Kobayashi Hironori, Yoshimura Norihiko, Suwabe Tatsuya, Katagiri Takayuki, Miyakoshi Shukuko, Ushiki Takashi, Fuse Kyoko, Shibasaki Yasuhiko, Moriyama Masato, Takizawa Jun, Narita Miwako, Sone Hirohito, Masuko Masayoshi

    臨床血液   57 ( 9 )   1524 - 1524   2016.9

     More details

    Language:English   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • The Dinakara equation for adjusting DLCO for hemoglobin in the HCT-CI is superior to the Cotes equation for predicting high-risk patients in allogeneic hematopoietic stem cell transplantation. Reviewed International journal

    Yasuhiko Shibasaki, Takayuki Katagiri, Hironori Kobayashi, Takashi Ushiki, Miwako Narita, Hirohito Sone, Tatsuo Furukawa, Masayoshi Masuko

    American journal of hematology   91 ( 5 )   E296 - E297   2016.5

     More details

    Language:English   Publisher:WILEY-BLACKWELL  

    DOI: 10.1002/ajh.24318

    Web of Science

    PubMed

    researchmap

  • Clinical Significance of MYC, BCL2 and BCL6 Rearrangement and Protein Expression in GCB and Non-GCB Type Diffuse Large B-Cell Lymphoma Invited Reviewed

    Keisuke Kawamoto, Jun Takizawa, Hiroaki Miyoshi, Noriaki Yoshida, Yasuhiko Shibasaki, Masayoshi Masuko, Hirohito Sone, Naoya Nakamura, Koichi Ohshima

    BLOOD   126 ( 23 )   2015.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:AMER SOC HEMATOLOGY  

    Web of Science

    researchmap

  • HSCT後のγ/δT細胞低値およびTreg細胞高値はいずれも再発の独立リスク因子である(Both low γ/δ T cells and high Treg cells after HSCT is an independent risk factor for relapse)

    Shibasaki Yasuhiko, Miyakoshi Syukuko, Suwabe Tatsuya, Katagiri Takayuki, Fuse Kyoko, Kobayashi Hironori, Ushiki Takashi, Moriyama Masato, Takizawa Jun, Narita Miwako, Sone Hirohito, Furukawa Tatsuo, Masuko Masayoshi

    臨床血液   56 ( 9 )   1666 - 1666   2015.9

     More details

    Language:English   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • レシピエントに対する移植前評価としてのHCT-CI/年齢スコアの臨床的意義(The clinical relevance of HCT-CI/age score as pre-transplant assessment for recipients)

    Katagiri Takayuki, Shibasaki Yasuhiko, Suwabe Tatsuya, Miyakoshi Shukuko, Fuse Kyoko, Kobayashi Hironori, Ushiki Takashi, Moriyama Masato, Takizawa Jun, Narita Miwako, Sone Hirohito, Masuko Masayoshi

    臨床血液   56 ( 9 )   1665 - 1665   2015.9

     More details

    Language:English   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • The association of level of reduction of Wilms' tumor gene 1 mRNA transcript in bone marrow and outcome in acute myeloid leukemia patients. Reviewed International journal

    Yasuhiko Shibasaki, Yoshinobu Seki, Tomoyuki Tanaka, Syukuko Miyakoshi, Kyoko Fuse, Takashi Kozakai, Hironori Kobayashi, Takashi Ushiki, Takashi Abe, Toshio Yano, Masato Moriyama, Takashi Kuroha, Noriatsu Isahai, Jun Takizawa, Miwako Narita, Satoru Koyama, Tatsuo Furukawa, Hirohito Sone, Masayoshi Masuko

    Leukemia research   39 ( 6 )   667 - 71   2015.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:PERGAMON-ELSEVIER SCIENCE LTD  

    We focused on the level of reduction of Wilms' tumor gene 1 (WT1) mRNA in bone marrow as minimal residual disease during chemotherapies in adult acute myeloid leukemia (AML) patients. Forty-eight patients were enrolled in this study. Log levels of reduction of WT1 mRNA transcript after induction therapy compared with those at diagnosis were associated with disease-free survival (DFS) (P=0.0066) and overall survival (OS) (P=0.0074) in patients who achieved complete remission. Also log levels of reduction of WT1 mRNA transcript after final consolidation therapy compared with those at diagnosis were associated with DFS (P=0.015) and OS (P=0.012). By multivariate analysis, log levels of reduction of WT1 mRNA transcript after induction therapy and after final consolidation therapy compared with those at diagnosis were extracted as risk factors for outcome. Our results suggest that early and deep reduction of tumor burden may be important for the outcome of AML patients. In addition, it may be useful for the decision to proceed with allogeneic SCT as post-remission therapy.

    DOI: 10.1016/j.leukres.2015.03.021

    Web of Science

    PubMed

    researchmap

  • Late onset post-transfusion hepatitis E developing during chemotherapy for acute promyelocytic leukemia. Reviewed

    Kyoko Fuse, Yuichi Matsuyama, Masato Moriyama, Shukuko Miyakoshi, Yasuhiko Shibasaki, Jun Takizawa, Tatsuo Furukawa, Ichiro Fuse, Hiro Matsumura, Shigeharu Uchida, Yoshifumi Takahashi, Kenya Kamimura, Hiroyuki Abe, Takeshi Suda, Yutaka Aoyagi, Hirohito Sone, Masayoshi Masuko

    Internal medicine (Tokyo, Japan)   54 ( 6 )   657 - 61   2015

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:JAPAN SOC INTERNAL MEDICINE  

    We herein report the case of a leukemia patient who developed hepatitis E seven months after undergoing a transfusion with contaminated blood products. The latency period in this case was significantly longer than that of typical hepatitis E. Recently, chronic infection with hepatitis E virus (HEV) genotype 3 has been reported in immunocompromised patients. There is a possibility that our patient was unable to eliminate the virus due to immunosuppression following chemotherapy and the administration of steroids. The prevalence of HEV in healthy Japanese individuals is relatively high and constitutes a critical source of infection via transfusion. Hepatitis E is an important post-transfusion infection, and immunocompromised patients may exhibit a long latency period before developing the disease.

    DOI: 10.2169/internalmedicine.54.2332

    Web of Science

    PubMed

    researchmap

  • Manifestations of Fulminant CD8 T-cell Post-transplant Lymphoproliferative Disorder Following the Administration of Rituximab for Lymphadenopathy with a High Level of Epstein-Barr Virus (EBV) Replication after Allogeneic Hematopoietic Stem Cell Transplantation Reviewed

    Tomoyuki Tanaka, Jun Takizawa, Shukuko Miyakoshi, Takashi Kozakai, Kyoko Fuse, Yasuhiko Shibasaki, Masato Moriyama, Koichi Ohshima, Ken Toba, Tatsuo Furukawa, Hirohito Sone, Masayoshi Masuko

    INTERNAL MEDICINE   53 ( 18 )   2115 - 2119   2014

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:JAPAN SOC INTERNAL MEDICINE  

    We herein report the case of a 22-year-old woman with severe aplastic anemia who underwent allogeneic hematopoietic stem cell transplantation (HSCT). After HSCT, the Epstein-Barr virus (EBV)-DNA load in the peripheral blood gradually increased, and the patient presented with a fever and lymphadenopathy on day 56 post-HSCT. Although we administered rituximab, her clinical condition worsened. After rituximab treatment, CD8 T-cells emerged and became dominant in the peripheral blood, some of which were positive on an EBV-specific tetramer analysis. However, an open biopsy of the lymphadenopathy lesions revealed the CD8 T-cells to be infected with EBV, exhibiting proliferation with oligoclonality. The patient ultimately died of multiple organ failure on day 99 post-HSCT.

    DOI: 10.2169/internalmedicine.53.2384

    Web of Science

    PubMed

    researchmap

  • Early Diagnosis of Hepatic Intravascular Lymphoma: A Case Report and Literature Review Reviewed

    Hiroyuki Abe, Kenya Kamimura, Maiko Mamizu, Yasuhiko Shibazaki, Takanobu Ishiguro, Shin-ichi Katada, Yu-ki Nishiyama, Yoshifumi Takahashi, Yu-ya Hatano, Ken-ichi Mizuno, Yukari Watanabe, Aiko Nagashima, Jun Takizawa, Manabu Takeuchi, Hirokazu Kawai, Minoru Nomoto, Hirohito Sone, Masatoyo Nishizawa, Yutaka Aoyagi

    INTERNAL MEDICINE   53 ( 6 )   587 - 593   2014

     More details

    Language:English   Publisher:JAPAN SOC INTERNAL MEDICINE  

    Hepatic intravascular large B-cell lymphoma (IVL) is a rare disease entity that involves invasion into various organs. Due to the aggressive behavior and poor prognosis of the disease and the difficulty in making an early diagnosis, some cases are diagnosed at autopsy. Early suspicion and the use of imaging studies and liver biopsies are key for diagnosing IVL; however, no reports have described the results of imaging studies due to the limited number of cases. We herein report the results of imaging studies of hepatic IVL, including the findings PET-CT, dynamic-CT, EOB-MRI and CEUS. These results may help physicians to make an early diagnosis and improve the prognosis.

    DOI: 10.2169/internalmedicine.53.1812

    Web of Science

    PubMed

    researchmap

  • Successful Treatment of Severe Newly Diagnosed Immune Thrombocytopenia Involving an Alveolar Hemorrhage with Combination Therapy Consisting of Romiplostim, Rituximab and Vincristine Reviewed

    Kiyoshi Okazuka, Masayoshi Masuko, Yuji Matsuo, Shukuko Miyakoshi, Tomoyuki Tanaka, Takashi Kozakai, Hironori Kobayashi, Kyoko Fuse, Yasuhiko Shibasaki, Masato Moriyama, Jun Takizawa, Ichiro Fuse, Ken Toba, Tatsuo Furukawa

    INTERNAL MEDICINE   52 ( 11 )   1239 - 1242   2013

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:JAPAN SOC INTERNAL MEDICINE  

    A 51-year-old man was admitted due to a severe bleeding tendency. After he was diagnosed with immune thrombocytopenia (ITP), several therapies, including steroids, steroid pulse, vincristine and rituximab, were administered; however, the patient's bleeding symptoms were not sufficiently controllable with these treatments. Subsequently, a diffuse alveolar hemorrhage was observed. Treatment with a thrombopoietin receptor agonist, romiplostim, was initiated to prevent lethal hemorrhaging, although the efficacy of thrombopoietic receptor agonists in such emergency situations has not been elucidated. The initiation of romiplostim achieved prompt remission in platelets. This case suggests that combination therapy with romiplostim, rituximab and vincristine is effective in cases of newly diagnosed severe therapy-resistant ITP.

    DOI: 10.2169/internalmedicine.52.0080

    Web of Science

    PubMed

    researchmap

  • AMLにおいて地固め療法後のWT1転写産物の減少は予後と関連している(Reduction value of WT1 transcripts after consolidation therapy is associated with prognosis in AML)

    Shibasaki Yasuhiko, Seki Yoshinobu, Koyama Satoru, Nikkuni Koji, Nomoto Nobuhiko, Isahai Noriatsu, Kuroha Takashi, Momoi Akihito, Yano Toshio, Ida Tori, Higashimura Masutaka, Kitajima Toshiki, Nanba Ayako, Kobayashi Hironori, Ushiki Takashi, Moriyama Masato, Okazuka Kiyoshi, Masuko Masayoshi, Toba Ken, Furukawa Tasuo

    臨床血液   53 ( 9 )   1179 - 1179   2012.9

     More details

    Language:English   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • Successful treatment of acute promyelocytic leukemia complicated with autoimmune hepatitis-induced portal hypertension with all-<i>trans</i> retinoic acid Reviewed

    USHIKI Takashi, NIKKUNI Koji, YOSHIDA Chie, SHIBASAKI Yasuhiko, ISHIKAWA Toru, MASUKO Masayoshi, TAKAI Kazue

    Rinsho Ketsueki   53 ( 1 )   97 - 104   2012

     More details

    Language:Japanese   Publisher:The Japanese Society of Hematology  

    A 35-year-old man admitted to the hospital for oral hemorrhage was diagnosed with acute promyelocytic leukemia (APL). Remission from APL was achieved by induction therapy with all-<i>trans</i> retinoic acid (ATRA); the <i>PML</i>/<i>RARA</i> fusion gene was not detected on PCR analysis. Despite complete molecular remission, severe persistent pancytopenia, massive ascites, and renal failure were observed. The liver surface appeared rough and irregular on computed tomographic images. On the basis of the liver biopsy results, we diagnosed his condition as portal hypertension due to autoimmune hepatitis. Indocyanine green test showed good residual function of the liver, and therefore, 2 courses of consolidation therapy were administered; chemotherapy was stopped because of severe pancytopenia due to portal hypertension. Instead of continuing the consolidation therapy, maintenance therapy involving 8 rounds of ATRA monotherapy (45 mg/m<sup>2</sup>, days1&sim;14) was initiated. Portal hypertension did not progress further with this maintenance therapy and therefore it was continued. The patient has been in remission from APL ever since, and no relapses have occurred since the past 5 years. These results suggest that ATRA can be used for long-term therapy in such cases.

    DOI: 10.11406/rinketsu.53.97

    PubMed

    CiNii Article

    CiNii Books

    researchmap

    Other Link: http://search.jamas.or.jp/link/ui/2012134493

  • Cardiogenic shock due to takotsubo cardiomyopathy during induction therapy for acute myeloid leukemia Reviewed

    USHIKI Takashi, NIKKUNI Koji, ISHIKAWA Yuya, SHIBASAKI Yasuhiko, HOSAKA Yukio, MASUKO Masayoshi, TAKAI Kazue

    Rinsho Ketsueki   52 ( 12 )   1896 - 1899   2011

     More details

    Language:Japanese   Publisher:The Japanese Society of Hematology  

    A 61-year-old man admitted for pancytopenia was diagnosed with acute myeloid leukemia. On day 26 of induction therapy, the patient suddenly developed cardiogenic shock. The ultrasound cardiogram showed imaging features typical of takotsubo cardiomyopathy. Cardiogenic shock caused by takotsubo cardiomyopathy is rare in patients with hematological malignancies but is a severe complication during chemotherapy.

    DOI: 10.11406/rinketsu.52.1896

    PubMed

    CiNii Article

    CiNii Books

    researchmap

    Other Link: http://search.jamas.or.jp/link/ui/2012156515

  • Myelodysplastic Syndrome with Ph Negative Monosomy 7 Chromosome following Transient Bone Marrow Dysplasia during Imatinib Treatment for Chronic Myeloid Leukemia Reviewed

    Kaori Karimata, Masayoshi Masuko, Takashi Ushiki, Takashi Kozakai, Yasuhiko Shibasaki, Toshio Yano, Takashi Abe, Masato Moriyama, Ken Toba, Tatsuo Furukawa, Yoshifusa Aizawa

    INTERNAL MEDICINE   50 ( 5 )   481 - 485   2011

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:JAPAN SOC INTERNAL MEDICINE  

    We describe a 60-year-old Japanese patient with chronic myeloid leukemia (CML) who developed myelodysplastic syndrome (MDS) with Ph negative monosomy 7 chromosome following transient bone marrow dysplasia during imatinib treatment. Most cases that developed chromosomal abnormality in Ph negative cells during imatinib therapy were reported to have less clinical implications, while rare cases developed MDS/AML. The present case suggested that metaphase karyotype analysis and bone marrow examination should be performed for the long term follow-up under imatinib treatment in cases showing cytopenia. The results also suggested that monosomy 7 in Ph negative cells may be an indicator of a poor prognosis.

    DOI: 10.2169/internalmedicine.50.4481

    Web of Science

    PubMed

    researchmap

  • Pharmacokinetic and pharmacodynamic analysis of cyclosporine A (CsA) to find the best single time point for the monitoring and adjusting of CsA dose using twice-daily 3-h intravenous infusions in allogeneic hematopoietic stem cell transplantation Reviewed

    Tatsuo Furukawa, Tori Kurasaki-Ida, Masayoshi Masuko, Nobuhiro Tsukada, Kiyoshi Okazuka, Naoko Sato, Toshio Yano, Takashi Abe, Akihito Momoi, Yasuhiko Shibasaki, Masutaka Higashimura, Kaori Karimata, Masato Moriyama, Takashi Kuroha, Jun Takizawa, Ken Toba, Miwako Narita, Ichiro Fuse, Masuhiro Takahashi, Yoshifusa Aizawa

    INTERNATIONAL JOURNAL OF HEMATOLOGY   92 ( 1 )   144 - 151   2010.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:SPRINGER TOKYO  

    Pharmacological study is predictably effective in establishing an optimal monitoring strategy for the usage of cyclosporine A (CsA) to prevent graft-versus-host disease (GVHD) in allogeneic hematopoietic stem cell transplantation recipients. Pharmacokinetic profiling of 33 recipients administered CsA twice daily by 3-h intravenous infusion revealed that levels peaked 2-3 h after the start of infusion, and an exponential decline of CsA concentrations after the termination of infusion was observed. The correlation between the area under the curve (AUC(0-12)) and CsA concentration at various time points after infusion revealed that C (2) and C (3) correlated best with AUC(0-12) (r (2) = 0.725), while the trough concentration correlated poorly. Ex vivo T cell stimulation followed by intracellular cytokine detection with flow cytometry revealed that the capacity of T cells to produce cytokines upon stimulation was inversely proportional to the CsA concentration, and reached a minimum at about 700 ng/mL with a marginal decrease above this concentration. Extrapolation using the regression equations of this study and the data from our retrospective study leads to the assumption that the dose adjustment of CsA based on maintaining the C (3) concentration above 800 ng/mL may effectively prevent acute GVHD. To confirm this assumption, a prospective clinical study is required.

    DOI: 10.1007/s12185-010-0610-0

    Web of Science

    PubMed

    researchmap

  • A chronic myeloid leukemia patient with atypical karyotype and BCR-ABL e13a3 transcript caused by complex chromosome rearrangement Reviewed

    Masayoshi Masuko, Tatsuo Furukawa, Takashi Abe, Reiko Wada, Soichi Maruyama, Toshiki Kitajima, Yasuhiko Shibasaki, Ken Toba, Masahiko Okada, Yoshifusa Aizawa

    INTERNATIONAL JOURNAL OF HEMATOLOGY   90 ( 2 )   230 - 234   2009.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:SPRINGER TOKYO  

    Philadelphia (Ph) chromosome as a result of t (9; 22) (q34; q11) is observed in more than 90% of chromic myeloid leukemia (CML) patients. Cases in which the typical Ph chromosome is not visible at the karyotype level comprise 5-10% of CML patients. CML cases with fusion transcripts such as e13a3 in which ABL exon 3 rather than exon 2 has fused to BCR are very rare. Such reported cases with the e13a3 transcript show the Ph chromosome on karyotype analysis. We reported an atypical karyotype CML patient with the e13a3 BCR-ABL transcript caused by complex translocation. Fluorescence in situ hybridization (FISH) analysis of the metaphase led to a precise cytogenetical characterization. The patient showed favorable response to imatinib, and achieved major molecular responses.

    DOI: 10.1007/s12185-009-0368-4

    Web of Science

    PubMed

    researchmap

  • [Effective combination chemotherapy with rituximab for acute lymphoblastic leukemia with bone relapse after bone marrow transplantation]. Reviewed

    Abe T, Kitajima T, Honma K, Kurasaki T, Okazuka K, Shibasaki Y, Momoi A, Kuroha T, Masuko M, Yagisawa K, Furukawa T, Toba K, Aizawa Y

    [Rinsho ketsueki] The Japanese journal of clinical hematology   49 ( 11 )   1556 - 1561   2008.11

  • [A short duration treatment with intensive consolidation therapy for patients with acute myelogenous leukemia--13 year experience in a single institute]. Reviewed

    Fujiwara M, Satou N, Izumi N, Shibasaki Y, Higashimura M, Tsukada N, Koike T

    Gan to kagaku ryoho. Cancer & chemotherapy   34 ( 11 )   1793 - 1798   2007.11

     More details

  • ATIII低下を伴うDICを合併したAPLの1例

    柴崎 康彦, 橋本 誠雄, 鳥羽 健, 柳川 貴央, 瀧澤 淳, 相澤 義房

    新潟医学会雑誌   116 ( 11 )   567 - 567   2002.11

▶ display all

MISC

  • Comparison of clinical outcomes among ATG and PTCY HLA-haploidentical HCT-single center analysis

    米沢穂高, 柴崎康彦, 武田ルイ, 片桐隆幸, 布施香子, 成田美和子, 曽根博仁, 増子正義

    日本造血細胞移植学会総会プログラム・抄録集   43rd   2021

  • 腫瘍抗原特異的CTLがNK細胞に及ぼす影響

    相原瞳, 佐藤廣幸, 諏訪部達也, 柴崎康彦, 増子正義, 内山孝由, 佐藤英世, 富山智香子, 曽根博仁, 成田美和子

    日本免疫治療学会学術集会プログラム・抄録集   18th   2021

  • Comparison of allo-HSCT for Primary induction failure and relapse acute myeloid leukemia

    布施香子, 武田ルイ, 水戸部正樹, 米沢穂高, 諏訪部達也, 片桐隆幸, 柴崎康彦, 曽根博仁, 増子正義

    日本造血細胞移植学会総会プログラム・抄録集   43rd   2021

  • AML with Major & minor-bcr/abl co-expressing clone after second hematopoietic cell transplants

    本宮奈津子, 本宮奈津子, 片桐隆幸, 武田ルイ, 水戸部正樹, 米沢穂高, 諏訪部達也, 布施香子, 柴崎康彦, 瀧澤淳, 曽根博仁, 増子正義

    日本造血細胞移植学会総会プログラム・抄録集   43rd   2021

  • Genetic Manipulation Resulting in Decreased Donor ChondroitinsulfateSynthesis Mitigates Gvhd Following Allogeneic Hematopoietic Cell Transplantation in a Murine Model

    Suguru Tamura, Takashi Ushiki, Tatsuya Suwabe, Takayuki Katagiri, Tomoyuki Tanaka, Kyoko Fuse, Yasuhiko Shibasaki, Miwako Narita, Michihiro Igarashi, Hirohito Sone, Masayoshi Masuko

    BLOOD   136   2020.11

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER SOC HEMATOLOGY  

    0

    DOI: 10.1182/blood-2020-137448

    Web of Science

    researchmap

  • Successful treatment for MDS-EB2 using ATG for GVHD prophylaxis in allogenic BMT from HLA two loci mismatch unrelated donor

    米沢穂高, 柴崎康彦, 笠見卓哉, 鈴木隆晴, 田村秀, 河本啓介, 布施香子, 瀧澤淳, 曽根博仁, 増子正義

    日本造血細胞移植学会総会プログラム・抄録集   42nd   2020

  • A case of MDS with graft failure in HLA 1 locus-mismatch rPBSCT after graft failure in HLA-matched urBMT

    笠見卓哉, 柴崎康彦, 米沢穂高, 田村秀, 鈴木隆晴, 河本啓介, 布施香子, 瀧澤淳, 曽根博仁, 増子正義

    日本造血細胞移植学会総会プログラム・抄録集   42nd   2020

  • MDS/AML-MRC as a poor risk factor for primary graft failure in allogeneic hematopoietic cell transplantation

    田村秀, 柴崎康彦, 米沢穂高, 鈴木隆晴, 笠見卓哉, 河本啓介, 布施香子, 瀧澤淳, 曽根博仁, 増子正義

    日本造血細胞移植学会総会プログラム・抄録集   42nd   2020

  • IMiDsがCTLとNK細胞に及ぼす効果

    佐藤廣幸, 諏訪部達也, 柴崎康彦, 増子正義, 内山孝由, 富山智香子, 渡邉香奈子, 高橋益廣, 曽根博仁, 成田美和子

    日本免疫治療学会学術集会プログラム・抄録集   17th   2020

  • 機能的なWT1特異的CD8陽性T細胞クローンは骨髄異形成症候群の骨髄内に集積する

    諏訪部達也, 柴崎康彦, 佐藤廣幸, 田村秀, 片桐隆幸, 根本洋樹, 笠見卓哉, 小堺貴司, 難波亜矢子, 北嶋俊樹, 布施香子, 牛木隆志, 曽根博仁, 成田美和子, 増子正義

    日本血液学会学術集会抄録(Web)   82nd   2020

  • 急性リンパ性白血病におけるCD123発現

    久保暢大, 馬場みのり, 申将守, 笠原靖史, 岩渕晴子, 今村勝, 柴崎康彦, 増子正義, 齋藤昭彦, 今井千速

    日本血液学会学術集会抄録(Web)   82nd   2020

  • 骨髄異形成症候群と低悪性度B細胞リンパ腫を合併し、多彩な合併症を呈した1例

    海發 茜, 小堺 貴司, 田村 秀, 片桐 隆幸, 河本 啓介, 難波 亜矢子, 布施 香子, 牛木 隆志, 柴崎 康彦, 森山 雅人, 瀧澤 淳, 成田 美和子, 曽根 博仁, 増子 正義

    臨床血液   60 ( 10 )   1503 - 1503   2019.10

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • Hodgkin lymphomaとAnaplastic large cell lymphomaの鑑別が困難であった巨大縦隔腫瘤を呈した1例

    河本 啓介, 鈴木 隆晴, 海發 茜, 田村 秀, 片桐 隆之, 難波 亜矢子, 布施 香子, 柴崎 康彦, 増子 正義, 曽根 博仁, 三好 寛明, 大島 孝一, 瀧澤 淳

    日本リンパ網内系学会会誌   59   133 - 133   2019.5

     More details

    Language:Japanese   Publisher:(一社)日本リンパ網内系学会  

    researchmap

  • 3度目の同種造血細胞移植後ポナチニブ維持療法を行い,寛解を維持している再発・難治Ph陽性ALL

    海發茜, 柴崎康彦, 諏訪部達也, 笠見卓哉, 田村秀, 片桐隆幸, 河本啓介, 難波亜矢子, 布施香子, 牛木隆志, 森山雅人, 瀧澤淳, 成田美和子, 曽根博仁, 増子正義

    日本造血細胞移植学会総会プログラム・抄録集   41st   173   2019.2

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • 非寛解期末梢血幹細胞移植後に通常量5‐AZA療法を施行し,寛解を維持しているEVI‐1陽性AMLの一例

    田村秀, 柴崎康彦, 上村駿, 笠見卓哉, 海發茜, 今西明, 片桐隆幸, 難波亜矢子, 河本啓介, 牛木隆志, 布施香子, 瀧澤淳, 成田美和子, 曽根博仁, 増子正義

    日本造血細胞移植学会総会プログラム・抄録集   41st   296   2019.2

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • 同種造血幹細胞移植後に再発した急性白血病の全生存とTRMの予後因子の検討

    布施香子, 諏訪部達也, 片桐隆幸, 柴崎康彦, 成田美和子, 曽根博仁, 増子正義

    日本造血細胞移植学会総会プログラム・抄録集   41st   2019

  • 同種造血細胞移植前のCT断面像による大腰筋面積測定は予後予測に有用である

    小林健太, 柴崎康彦, 柴崎康彦, 布施香子, 曽根博仁, 増子正義

    日本造血細胞移植学会総会プログラム・抄録集   41st   2019

  • ATRA・ATO併用療法により寛解を維持している再発性治療関連急性前骨髄白血病の1例

    前田 愁一郎, 布施 香子, 諏訪部 達也, 笠見 卓哉, 河本 啓介, 田中 智之, 難波 亜矢子, 小林 弘典, 柴崎 康彦, 瀧澤 淳, 成田 美和子, 曽根 博仁, 増子 正義

    臨床血液   59 ( 11 )   2496 - 2496   2018.11

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • 人工知能を用いて患者の病態に合わせた最も効果的な同種造血細胞移植法を選択する試み

    布施 香子, 柴崎 康彦, 古川 達雄, 曽根 博仁, 増子 正義

    新潟県医師会報   ( 824 )   9 - 10   2018.11

     More details

    Language:Japanese   Publisher:新潟県医師会  

    researchmap

  • Clinical Features and Risk Factors of Post-Engraftment Bloodstream Infection in Allogeneic HCT

    Tatsuya Suwabe, Kyoko Fuse, Takayuki Katagiri, Tomoyuki Tanaka, Takashi Ushiki, Yasuhiko Shibasaki, Miwako Narita, Hirohito Sone, Masayoshi Masuko

    BLOOD   132   2018.11

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER SOC HEMATOLOGY  

    0

    DOI: 10.1182/blood-2018-99-115844

    Web of Science

    researchmap

  • Marker Chromosomes Are a New Cytogenetic Adverse Risk Factor in AML after Allo-HCT

    Kyoko Fuse, Tomoyuki Tanaka, Shun Uemura, Tatsuya Suwabe, Takayuki Katagiri, Takashi Ushiki, Yasuhiko Shibasaki, Naoko Sato, Toshio Yano, Takashi Kuroha, Shigeo Hashimoto, Tastuo Furukawa, Miwako Narita, Hirohito Sone, Masayoshi Masuko

    BLOOD   132   2018.11

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER SOC HEMATOLOGY  

    0

    DOI: 10.1182/blood-2018-99-113251

    Web of Science

    researchmap

  • Distinct Effects of Chondroitin Sulfate on Hematopoietic Cells and the Stromal Microenvironment in Bone Marrow Hematopoiesis

    Takayuki Katagiri, Takashi Ushiki, Asami Kawasaki, Shun Uemura, Tatsuya Suwabe, Tomoyuki Tanaka, Kyoko Fuse, Yasuhiko Shibasaki, Hirohito Sone, Michihiro Igarashi, Masayoshi Masuko

    BLOOD   132   2018.11

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER SOC HEMATOLOGY  

    0

    DOI: 10.1182/blood-2018-99-115796

    Web of Science

    researchmap

  • ATRA・ATO併用療法により寛解を維持している再発性治療関連急性前骨髄白血病の1例

    前田 愁一郎, 布施 香子, 諏訪部 達也, 笠見 卓哉, 河本 啓介, 田中 智之, 難波 亜矢子, 小林 弘典, 柴崎 康彦, 瀧澤 淳, 成田 美和子, 曽根 博仁, 増子 正義

    臨床血液   59 ( 11 )   2496 - 2496   2018.11

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    J-GLOBAL

    researchmap

  • 濾胞性リンパ腫初回診断時におけるアグレッシブリンパ腫への形質転換予測(MYC copy number predicts histologic transformation of follicular lymphoma to aggressive lymphoma)

    桐生 真依子, 河本 啓介, 鈴木 隆晴, 田村 秀, 上村 駿, 海發 茜, 諏訪部 達也, 今西 明, 笠見 卓哉, 根本 洋樹, 片桐 隆幸, 田中 智之, 難波 亜矢子, 布施 香子, 柴崎 康彦, 増子 正義, 曽根 博仁, 三好 寛明, 瀬戸 加大, 大島 孝一, 瀧澤 淳

    臨床血液   59 ( 9 )   1593 - 1593   2018.9

     More details

    Language:English   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • 単一施設におけるATGとPTCYを用いた半合致移植の後方視解析(Clinical analysis of haploidentical transplantation using ATG and PTCY in single institute)

    田中 智之, 上村 駿, 海發 茜, 田村 秀, 諏訪部 達也, 片桐 隆幸, 河本 啓介, 布施 香子, 牛木 隆志, 柴崎 康彦, 瀧澤 淳, 成田 美和子, 曽根 博仁, 増子 正義

    臨床血液   59 ( 9 )   1678 - 1678   2018.9

     More details

    Language:English   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • 寛解期急性白血病に対する同種移植のドナーソース別入院費の比較(Hospitalization costs of allo-HCT among donor sources for acute leukemia in complete remission)

    難波 亜矢子, 柴崎 康彦, 上村 駿, 諏訪部 達也, 片桐 隆幸, 田中 智之, 布施 香子, 成田 美和子, 曽根 博仁, 増子 正義

    臨床血液   59 ( 9 )   1680 - 1680   2018.9

     More details

    Language:English   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • 同種造血幹細胞移植における強化口腔ケアは生着後の血流感染を減少させる(Intensive oral care can reduce blood stream infection post neutrophil engraftment in allogeneic HCT)

    諏訪部 達也, 布施 香子, 勝良 剛詞, 田中 恵子, 片桐 隆幸, 田中 智之, 牛木 隆志, 柴崎 康彦, 成田 美和子, 曽根 博仁, 増子 正義

    臨床血液   59 ( 9 )   1536 - 1536   2018.9

     More details

    Language:English   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • G-CSFを産生し初回治療中に再発したびまん性大細胞型B細胞性リンパ腫の1例

    笠見 卓哉, 河本 啓介, 鈴木 隆晴, 田中 智之, 布施 香子, 柴崎 康彦, 増子 正義, 成田 美和子, 曽根 博仁, 大島 孝一, 瀧澤 淳

    日本リンパ網内系学会会誌   58   114 - 114   2018.5

     More details

    Language:Japanese   Publisher:(一社)日本リンパ網内系学会  

    researchmap

  • GDP療法がtriple-hit lymphomaの救援療法として有効であった1例

    水戸部 正樹, 河本 啓介, 鈴木 隆晴, 田村 秀, 小堺 貴司, 難波 亜矢子, 諏訪部 達也, 笠見 卓哉, 田中 智之, 布施 香子, 柴崎 康彦, 増子 正義, 曽根 博仁, 大島 孝一, 瀧澤 淳

    臨床血液   59 ( 5 )   620 - 621   2018.5

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • ビタミンD3産生性と考えられるALK陰性未分化大細胞リンパ腫の1例

    水戸部 正樹, 河本 啓介, 鈴木 隆晴, 難波 亜矢子, 柴崎 康彦, 増子 正義, 曽根 博仁, 三好 寛明, 大島 孝一, 瀧澤 淳

    日本リンパ網内系学会会誌   58   121 - 121   2018.5

     More details

    Language:Japanese   Publisher:(一社)日本リンパ網内系学会  

    researchmap

  • GDP療法がtriple-hit lymphomaの救援療法として有効であった1例

    水戸部 正樹, 河本 啓介, 鈴木 隆晴, 田村 秀, 小堺 貴司, 難波 亜矢子, 諏訪部 達也, 笠見 卓哉, 田中 智之, 布施 香子, 柴崎 康彦, 増子 正義, 曽根 博仁, 大島 孝一, 瀧澤 淳

    臨床血液   59 ( 5 )   620 - 621   2018.5

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • Antigen specific INF-γproduction of the amplified CTL using plasmacytoid dendritic cell line (PMDC11)

    Yamada Syunya, Goto Wakana, Ogawa Sara, Masuko Masayoshi, Kobayashi Kaho, Shibasaki Yasuhiko, Uchiyama Takayoshi, Takizawa Jun, Sone Hirohito, Takahashi Masuhiro, Narita Miwako

    新潟大学保健学雑誌 = Journal of health sciences of Niigata University   15 ( 1 )   9 - 17   2018.3

     More details

    Language:Japanese   Publisher:新潟大学医学部保健学科  

    It is becoming clear that antigen-specific cytotoxic T cells (CTLs) play an important role in anti-tumor immune system due to the recent confirmation of clinical effects of immune-checkpoint inhibitors. We tried to amplify efficiently WT1 specific oligoclonal CTLs from the peripheral blood of the case treated with WT1 peptide vaccine using dendritic cell line PMDC 11 which was established in our laboratory. Antigen - specific IFN - γ - producing ability was confirmed in the amplified WT1- specific CTLs. This result means that the antigen - specific CTLs amplified by PMDC 11 maintain cytotoxic ability against to tumor specific antigen. This method of amplifying antigen-specific CTLs using MLPC and PMDC 11 will lead to application of CTL to clinical application and TCR and surface antigen analysis.

    CiNii Article

    CiNii Books

    researchmap

    Other Link: http://hdl.handle.net/10191/49822

  • Enhancement of antigen-specific CTL inducing ability in leukemic plasmacytoid dendritic cells (PMDC11) using CpG-B

    Goto Wakana, Yamada Syunya, Hashimoto Shigeo, Masuko Masayoshi, Kobayashi Kaho, Ogawa Sara, Shibasaki Yasuhiko, Sone Hirohito, Takahashi Masuhiro, Narita Miwako

    新潟大学保健学雑誌 = Journal of health sciences of Niigata University   15 ( 1 )   1 - 8   2018.3

     More details

    Language:Japanese   Publisher:新潟大学医学部保健学科  

    The leukemic plasmacytoid dendritic cell line (PMDC05) transduced with CD80 gene, which was previously established in our laboratory, was named PMDC11. PMDC11 cells have potent antigen-presenting ability. In this study, for the purpose to develop methods to examine the appearance of the immune checkpoints between tumor cells and antigen-specific cytotoxic T cells (CTLs) and to analyze those CTL function, we tried the expansion of WT1 specific CTL using PMDC11 as APCs. PMDC11 stimulated with CpG-B for 24 hours slightly enhanced the co-stimulatory factors CD40 and CD83 without increasing the expression of co-inhibitory factor PD-L1 and PD-L2. PMDC11 cells, which were pulsed WT1 peptide and stimulated with CpG-B, were co-cultured with WT1 / MHC-tetramer+ cells for 24 hours. As a result, the amplification of WT1 peptide antigen specific CTL was observed remarkably. Therefore, this amplification method is useful for development of an examination method on the strength of the immunity checkpoint, and it can be applied in the functional analysis of the anti-tumor antigen-specific CTL.

    CiNii Article

    CiNii Books

    researchmap

    Other Link: http://hdl.handle.net/10191/49818

  • 樹状細胞由来細胞株を用いて増幅したWT1特異的細胞傷害性T細胞(CTL)のINF-γ産生能の検討

    山田 峻也, 後藤 若奈, 小川 彩空, 増子 正義, 小林 果歩, 柴崎 康彦, 内山 孝由, 瀧澤 惇, 曽根 博仁, 高橋 益廣, 成田 美和子

    新潟大学保健学雑誌   15 ( 1 )   9 - 17   2018.3

     More details

    Language:Japanese   Publisher:新潟大学医学部保健学科  

    免疫チェックポイント阻害薬の臨床的効果により、抗原特異的細胞傷害性T細胞(CTL)が抗腫瘍作用において重要な役割を果たしていることが明らかとなった。腫瘍に対するCTLの臨床効果を予測する解析のためには、個別のヒトCTLの簡便なクローン性の増幅方法の開発が必要である。我々は、MLPC法と強力な抗原提示能を有する樹状細胞株PMDC11を用いてWT1特異的CTLのクローン性増幅を試みた。数個のCTLから4週間の培養によって増幅した細胞群にはWT1特異的IFN-γ産生が確認された。この抗原特異的CTLの簡便で効率的な増幅方法は、免疫チェックポイント阻害因子、T細胞受容体(TCR)や腫瘍特異的表面抗原の解析に応用可能と思われた。(著者抄録)

    researchmap

  • CpG-Bを用いた白血病性形質細胞様樹状細胞(PMDC11)における抗原特異的CTL誘導能の増強

    後藤 若奈, 山田 峻也, 橋本 誠雄, 増子 正義, 小林 果歩, 小川 彩空, 柴崎 康彦, 曽根 博仁, 高橋 益廣, 成田 美和子

    新潟大学保健学雑誌   15 ( 1 )   1 - 8   2018.3

     More details

    Language:Japanese   Publisher:新潟大学医学部保健学科  

    本研究室では、樹立した白血病性形質細胞様樹状細胞株PMDC05へCD80遺伝子を導入することにより強力な抗原提示能をもつPMDC11を作成している。腫瘍細胞とその腫瘍に対する抗原特異的細胞傷害性T細胞(CTL)との間の免疫チェックポイントの強度に関する検査法開発を目指した基礎的研究としてPMDC11のCpG-Bによる機能の変化の有無と腫瘍抗原特異的CTLの増幅効果を検討した。CpG-B刺激は共抑制因子PD-L1及びPD-L2の発現を増加させることなく共刺激因子CD40及びCD83をわずかに高めた。WT1ペプチドパルスに加えてCpG-B刺激したPMDC11とWT1/MHC-tetramer+細胞との共培養を行ったところ、WT1ペプチド抗原特異的CTLの著しい増加が認められた。この培養法は、腫瘍抗原特異的CTLの機能解析において応用可能と考えられた。(著者抄録)

    researchmap

  • Intrabone single unit cord blood transplantation for hematological malignancies Reviewed

    Murata Makoto, Maeda Yoshinobu, Masuko Masayoshi, Fukuhara Noriko, Nishida Tetsuya, Terakura Seitaro, Ishikawa Yuichi, Tanimoto Mitsune, Shibasaki Yasuhiko, Suzuki Ritsuro, Kodera Yoshihisa, Kiyoi Hitoshi, Naoe Tomoki

    CANCER SCIENCE   109   757-757   2018.1

     More details

    Language:English   Publishing type:Rapid communication, short report, research note, etc. (scientific journal)  

    researchmap

  • Methotrexate大量療法後の高度排泄遅延および急性腎障害に対して血液浄化法が有用であったALL患者の1例

    森紗世子, 難波亜矢子, 後藤千尋, 柴崎康彦, 柴崎康彦, 増子正義, 曽根博仁, 後藤佐和子, 細島康宏, 山本卓, 成田一衛, 島田泉, 鈴木直人, 外山聡

    日本医療薬学会年会講演要旨集(Web)   28   2018

  • Methotrexate大量療法後の高度排泄遅延および急性腎障害に対して血液浄化療法が有用であったALL患者の1例

    森紗世子, 後藤佐和子, 細島康宏, 山本卓, 成田一衛, 難波亜矢子, 後藤千尋, 柴崎康彦, 柴崎康彦, 増子正義, 曽根博仁, 島田泉, 鈴木直人, 外山聡

    東北腎不全研究会プログラム・抄録集   45th   2018

  • WT1ペプチドワクチン施行例における長期残存WT1-tetramer陽性細胞の機能解析及び増幅

    後藤若奈, 小川彩空, 増子正義, 諏訪部達也, 田中智之, 内山孝由, 橋本誠雄, 柴崎康彦, 高橋益廣, 成田美和子

    日本免疫治療学研究会学術集会プログラム・抄録集   15th   2018

  • 多職種連携チーム医療が著効した食道慢性GVHDの一例

    難波亜矢子, 上村駿, 諏訪部達也, 笠見卓哉, 河本啓介, 河本啓介, 田中智之, 小林弘典, 布施香子, 小師優子, 真柄仁, 高昌良, 冨永顕太郎, 橋本哲, 横山純二, 柴崎康彦, 柴崎康彦, 瀧澤淳, 曽根博仁, 増子正義

    日本造血細胞移植学会総会プログラム・抄録集   40th   305   2017.12

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • マーカー染色体が急性骨髄性白血病に対する同種造血細胞移植成績に与える影響

    田中智之, 布施香子, 諏訪部達也, 笠見卓哉, 河本啓介, 河本啓介, 牛木隆志, 森山雅人, 柴崎康彦, 柴崎康彦, 瀧澤淳, 成田美和子, 曽根博仁, 増子正義, 増子正義

    日本造血細胞移植学会総会プログラム・抄録集   40th   239   2017.12

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • Patient-Based Prediction Algorithm of Relapse after Allo-HSCT for Acute Leukemia Using Machine Learning Approach

    Kyoko Fuse, Shun Uemura, Tatsuya Suwabe, Takayuki Katagiri, Tomoyuki Tanaka, Takashi Ushiki, Yasuhiko Shibasaki, Naoko Sato, Toshio Yano, Takashi Kuroha, Shigeo Hashimoto, Tastuo Furukawa, Miwako Narita, Hirohito Sone, Masayoshi Masuko

    BLOOD   130   2017.12

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER SOC HEMATOLOGY  

    0

    Web of Science

    researchmap

  • Further Prognostic Factors for Stratification of Patients in the High-Risk HCT-CI Group Undergoing Allogeneic HCT

    Yasuhiko Shibasaki, Tatsuya Suwabe, Shun Uemura, Takayuki Katagiri, Tomoyuki Tanaka, Takashi Ushiki, Kyoko Fuse, Miwako Narita, Hirohito Sone, Masayoshi Masuko

    BLOOD   130   2017.12

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER SOC HEMATOLOGY  

    0

    Web of Science

    researchmap

  • HLA半合致移植後AMLとして再発したB-ALLの1例

    小堺 貴司, 田村 秀, 布施 香子, 柴崎 康彦, 瀧澤 淳, 曽根 博仁, 増子 正義

    臨床血液   58 ( 11 )   2270 - 2271   2017.11

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • 4 当科におけるMTX関連リンパ増殖性疾患の後方視的解析 (Ⅰ.一般演題, 第104回膠原病研究会)

    131 ( 10 )   618 - 618   2017.10

  • 抗原特異的細胞傷害性T細胞(CTL)の増幅と機能の検討

    小川 彩空, 増子 正義, 後藤 若奈, 内山 孝由, 橋本 誠雄, 柴崎 康彦, 瀧澤 淳, 成田 美和子

    日臨技北日本支部医学検査学会抄録集   6回   128 - 128   2017.10

     More details

    Language:Japanese   Publisher:日臨技北日本支部医学検査学会  

    researchmap

  • 血液悪性疾患に対する骨髄内臍帯血移植

    村田 誠, 前田 嘉信, 増子 正義, 福原 規子, 西田 徹也, 寺倉 精太郎, 石川 裕一, 谷本 光音, 柴崎 康彦, 鈴木 律朗, 小寺 良尚, 清井 仁, 直江 知樹

    日本癌学会総会記事   76回   P - 2373   2017.9

     More details

    Language:English   Publisher:日本癌学会  

    researchmap

  • 臍帯血移植後にヒトパルボウイルスB19感染による自己免疫性溶血性貧血と赤芽球癆を発症した1例

    海發 茜, 柴崎 康彦, 上村 駿, 田村 秀, 小堺 貴司, 難波 亜矢子, 小林 弘典, 布施 香子, 牛木 隆志, 森山 雅人, 瀧澤 淳, 成田 美和子, 曽根 博仁, 増子 正義

    臨床血液   58 ( 8 )   1078 - 1078   2017.8

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • 同種造血幹細胞移植において生着後早期の免疫再構築はドナーソースや移植法により異なる

    上村駿, 柴崎康彦, 片桐隆幸, 井藤ヒロミ, 海發茜, 田村秀, 鈴木隆晴, 根本洋樹, 小林弘典, 布施香子, 牛木隆志, 森山雅人, 瀧澤淳, 成田美和子, 曽根博仁, 増子正義

    日本造血細胞移植学会総会プログラム・抄録集   39th   237   2017.2

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • 移植後長期フォローアップにおける再発の早期発見を目的とした末梢血STR法の有用性

    海發茜, 柴崎康彦, 中村岳史, 椎谷恵子, 和田玲子, 田村秀, 鈴木隆晴, 上村駿, 片桐隆幸, 根元洋樹, 小林弘典, 布施香子, 牛木隆志, 森山雅人, 瀧澤淳, 成田美和子, 曽根博仁, 増子正義

    日本造血細胞移植学会総会プログラム・抄録集   39th   252   2017.2

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • 樹木構造接近法を用いた急性白血病,骨髄異形成症候群に対する造血細胞移植後の予後因子の解析

    布施香子, 上村駿, 海發茜, 鈴木隆晴, 田村秀, 片桐隆幸, 根本洋樹, 小林弘典, 牛木隆志, 柴崎康彦, 森山雅人, 瀧澤淳, 成田美和子, 曽根博仁, 増子正義

    日本造血細胞移植学会総会プログラム・抄録集   39th   247   2017.2

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • 破壊性甲状腺炎をともなったMYC転座陽性甲状腺悪性リンパ腫の1例

    山田 貴穂, 布施 香子, 柴崎 康彦, 河本 啓介, 羽入 修, 瀧澤 淳, 大島 孝一, 曽根 博仁

    日本内分泌学会雑誌   92 ( 3 )   635 - 635   2017.1

     More details

    Language:Japanese   Publisher:(一社)日本内分泌学会  

    researchmap

  • 抗CCR4抗体併用化学療法による寛解後の臍帯血移植が奏効した成人T細胞白血病リンパ腫

    諏訪部 達也, 柴崎 康彦, 海發 茜, 片桐 隆幸, 宮腰 淑子, 布施 香子, 小林 弘典, 牛木 隆志, 森山 雅人, 瀧澤 淳, 成田 美和子, 曽根 博仁, 増子 正義

    臨床血液   58 ( 1 )   32 - 36   2017.1

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    症例は成人T細胞白血病/リンパ腫(ATLL)急性型の62歳男性。CHOP療法単独では治療抵抗性であったが,抗CCR4抗体mogamulizumab併用CHOP療法が奏効し寛解を得た。HLA一致血縁・非血縁ドナーが得られず,mogamulizumab最終投与後71日目に骨髄非破壊的前処置を用いた臍帯血移植を施行した。急性移植片対宿主病(GVHD)grade II(皮膚stage2)を発症したが,methylprednisolone投与により制御可能であり,移植後9ヵ月時点まで寛解を維持している。経過中,制御性T細胞(Treg)は著減したままの状態であった。同種造血幹細胞移植はATLLの根治的治療であるが,移植前にmogamulizumabを使用する際,Tregの減少による急性GVHDの発症頻度・重症度が増加する可能性が報告されている。寛解期移植を目指すためにmogamulizumabを使用せざるを得ない症例における至適なドナーソースや移植時期,GVHD予防法に関して,更なる症例の蓄積が望まれる。(著者抄録)

    J-GLOBAL

    researchmap

  • 同種造血細胞移植後の免疫再構築に関与する因子の同定および、それらの因子を用いた予後予測モデルの構築

    柴崎 康彦, 曽根 博仁, 増子 正義

    新潟県医師会報   ( 802 )   9 - 10   2017.1

     More details

    Language:Japanese   Publisher:新潟県医師会  

    researchmap

  • Myelodysplastic syndrome with refractory hemorrhage due to reduced platelet aggregation activity

    TANAKA Tomoyuki, SONE Hirohito, FUSE Ichiro, MASUKO Masayoshi, KOZAKAI Takashi, KITAJIMA Toshiki, FUSE Kyoko, KOBAYASHI Hironori, USHIKI Takashi, SHIBAZAKI Yasuhiko, MORIYAMA Masato, TAKIZAWA Jun

    Rinsho Ketsueki   58 ( 12 )   2402 - 2405   2017

     More details

    Language:Japanese   Publisher:The Japanese Society of Hematology  

    <p>A 75-year-old woman suffered a cat bite 10 months after myelodysplastic syndrome (MDS) diagnosis. She visited our hospital because the internal bleeding of the wound did not improve. Although the wound was treated, the bleeding did not stop. She was hospitalized for emergency medical treatment because the bleeding volume exceeded 200 m<i>l</i>. Although her platelet count was normal, the platelet function test showed a decrease in collagen and arachidonic acid aggregation. After platelet transfusion, her bleeding stopped. Patients with MDS may potentially have platelet dysfunction. In the case of bleeding without thrombocytopenia, a platelet function test should be performed and treatment intervention, such as platelet transfusion, should be considered.</p>

    DOI: 10.11406/rinketsu.58.2402

    CiNii Article

    CiNii Books

    researchmap

    Other Link: http://search.jamas.or.jp/link/ui/2018121562

  • Peripheral T-cell lymphoma, not otherwise specified: a retrospective single-center analysis

    SUZUKI Takaharu, SHIBAZAKI Yasuhiko, MORIYAMA Masato, MASUKO Masayoshi, NARITA Miwako, SONE Hirohito, AOKI Sadao, NAKAMURA Naoya, OSHIMA Koichi, TAKIZAWA Jun, KAWAMOTO Keisuke, TAMURA Suguru, UEMURA Shun, KAIHATSU Akane, NEMOTO Hiroki, KOBAYASHI Hironori, USHIKI Takashi, FUSE Kyoko

    Rinsho Ketsueki   58 ( 8 )   905 - 911   2017

     More details

    Language:Japanese   Publisher:The Japanese Society of Hematology  

    <p>We retrospectively analyzed clinical and pathological features, treatments, and prognoses in 28 patients with newly diagnosed peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) in Niigata University Medical and Dental Hospital. Of them, 16 were males and 12 were females, and their median age was 62.5 (range, 26-88) years. The International Prognostic Index was high-intermediate/high in 68% of patients. Twelve patients were treated with CHOP/THP-COP and nine with third-generation chemotherapy regimens. At a median follow-up period of 30 (range: 1-164) months, the 2-year overall survival and progression-free survival rates were 61% and 44%, respectively. Further investigation of novel agents for treating PTCL-NOS is warranted.</p>

    DOI: 10.11406/rinketsu.58.905

    CiNii Article

    CiNii Books

    researchmap

    Other Link: http://search.jamas.or.jp/link/ui/2017376952

  • 機械学習を用いた急性白血病における造血幹細胞移植後の患者ベースの再発予測モデルと個別化治療への応用

    布施香子, 上村駿, 諏訪部達也, 片桐隆幸, 笠見卓哉, 田中智之, 難波亜矢子, 牛木隆志, 柴崎康彦, 柴崎康彦, 佐藤直子, 矢野敏雄, 黒羽高志, 橋本誠雄, 古川達雄, 成田美和子, 曽根博仁, 増子正義

    日本造血細胞移植学会総会プログラム・抄録集   40th   2017

  • Evaluation of Liver Iron Deposition in Transfusion-Dependent Patients By Dual-Energy CT

    Hironori Kobayashi, Norihiko Yoshimura, Takayuki Katagiri, Takashi Ushiki, Kyoko Fuse, Yasuhiko Shibasaki, Miwako Narita, Hirohito Sone, Masayoshi Masuko

    BLOOD   128 ( 22 )   2016.12

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER SOC HEMATOLOGY  

    0

    DOI: 10.1182/blood.V128.22.3619.3619

    Web of Science

    researchmap

  • The Predictive Factors of Favorable Prognosis after Allo-HSCT for Refractory Acute Leukemia

    Kyoko Fuse, Takayuki Katagiri, Yasuhiko Shibasaki, Tomoyuki Tanaka, Miwako Narita, Hirohito Sone, Masayoshi Masuko, Tatsuo Furukawa, Naoko Sato, Toshio Yano, Takashi Kuroha, Shigeo Hashimoto, Takashi Ushiki

    BLOOD   128 ( 22 )   2016.12

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER SOC HEMATOLOGY  

    0

    DOI: 10.1182/blood.V128.22.2297.2297

    Web of Science

    researchmap

  • Intrabone Transplantation of a Single Cord Blood Unit Using Non-Irradiated Reduced-Intensity Conditioning

    Makoto Murata, Yoshinobu Maeda, Masayoshi Masuko, Yasushi Onishi, Tomoyuki Endo, Seitaro Terakura, Yuichi Ishikawa, Chisako Iriyama, Yoko Ushijima, Tatsunori Goto, Nobuharu Fujii, Mitsune Tanimoto, Hironori Kobayashi, Yasuhiko Shibasaki, Noriko Fukuhara, Yoshihiro Inamoto, Ritsuro Suzuki, Tadashi Matsushita, Yoshihisa Kodera, Hitoshi Kiyoi, Tomoki Naoe, Tetsuya Nishida

    BLOOD   128 ( 22 )   2016.12

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER SOC HEMATOLOGY  

    Web of Science

    researchmap

  • 多発血栓を来したTAFRO症候群の1例

    上村 駿, 小林 弘典, 田村 秀, 鈴木 隆晴, 海發 茜, 河本 啓介, 笠見 卓哉, 根本 洋樹, 布施 香子, 柴崎 康彦, 増子 正義, 曽根 博仁, 大島 孝一, 瀧澤 淳

    臨床血液   57 ( 11 )   2423 - 2423   2016.11

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • 扁桃・リンパ節に多発性myeloid sarcomaを生じたMDSの1例

    片桐 隆幸, 牛木 隆志, 田中 智之, 宮腰 淑子, 難波 亜矢子, 河本 啓介, 柴崎 康彦, 瀧澤 淳, 成田 美和子, 曽根 博仁, 青木 定夫, 増子 正義

    臨床血液   57 ( 11 )   2415 - 2415   2016.11

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • 当科におけるPTCL、NOS 28例の臨床病理学的解析

    鈴木 隆晴, 田村 秀, 上村 俊, 海發 茜, 河本 啓介, 根本 洋樹, 小林 弘典, 牛木 隆志, 布施 香子, 柴崎 康彦, 森山 雅人, 増子 正義, 成田 美和子, 曽根 博仁, 青木 定夫, 中村 直哉, 大島 孝一, 瀧澤 淳

    臨床血液   57 ( 11 )   2426 - 2426   2016.11

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • HLA半合致移植を施行した最重症再生不良性貧血の1例

    宮腰 淑子, 柴崎 康彦, 諏訪部 達也, 片桐 隆幸, 小林 弘典, 布施 香子, 森山 雅人, 瀧澤 淳, 成田 美和子, 曽根 博仁, 増子 正義

    臨床血液   57 ( 11 )   2416 - 2416   2016.11

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • 多発血栓を来したTAFRO症候群の1例

    上村 駿, 小林 弘典, 田村 秀, 鈴木 隆晴, 海發 茜, 河本 啓介, 笠見 卓哉, 根本 洋樹, 布施 香子, 柴崎 康彦, 増子 正義, 曽根 博仁, 大島 孝一, 瀧澤 淳

    臨床血液   57 ( 11 )   2423 - 2423   2016.11

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • 扁桃・リンパ節に多発性myeloid sarcomaを生じたMDSの1例

    片桐 隆幸, 牛木 隆志, 田中 智之, 宮腰 淑子, 難波 亜矢子, 河本 啓介, 柴崎 康彦, 瀧澤 淳, 成田 美和子, 曽根 博仁, 青木 定夫, 増子 正義

    臨床血液   57 ( 11 )   2415 - 2415   2016.11

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    J-GLOBAL

    researchmap

  • 当科におけるPTCL、NOS 28例の臨床病理学的解析

    鈴木 隆晴, 田村 秀, 上村 俊, 海發 茜, 河本 啓介, 根本 洋樹, 小林 弘典, 牛木 隆志, 布施 香子, 柴崎 康彦, 森山 雅人, 増子 正義, 成田 美和子, 曽根 博仁, 青木 定夫, 中村 直哉, 大島 孝一, 瀧澤 淳

    臨床血液   57 ( 11 )   2426 - 2426   2016.11

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • HLA半合致移植を施行した最重症再生不良性貧血の1例

    宮腰 淑子, 柴崎 康彦, 諏訪部 達也, 片桐 隆幸, 小林 弘典, 布施 香子, 森山 雅人, 瀧澤 淳, 成田 美和子, 曽根 博仁, 増子 正義

    臨床血液   57 ( 11 )   2416 - 2416   2016.11

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    J-GLOBAL

    researchmap

  • PCNSL寛解後12年を経て発症した副鼻腔DLBCLで、繰り返す皮膚再発に対して少量経口エトポシド療法が有効であった1症例

    田村 秀, 大橋 瑠子, 梅津 哉, 諏訪部 達也, 片桐 隆幸, 河本 啓介, 宮腰 淑子, 北嶋 俊樹, 柴崎 康彦, 曽根 博仁, 青木 洋, 大島 孝一, 瀧澤 淳

    日本リンパ網内系学会会誌   56   98 - 98   2016.8

     More details

    Language:Japanese   Publisher:(一社)日本リンパ網内系学会  

    researchmap

  • 当科におけるIVLBCL 14例の臨床病理学的検討

    諏訪部 達也, 河本 啓介, 片桐 隆幸, 宮腰 淑子, 小林 弘典, 牛木 隆志, 布施 香子, 柴崎 康彦, 森山 雅人, 増子 正義, 成田 美和子, 曽根 博仁, 瀧澤 淳, 中村 直哉, 大島 孝一

    日本リンパ網内系学会会誌   56   92 - 92   2016.8

     More details

    Language:Japanese   Publisher:(一社)日本リンパ網内系学会  

    researchmap

  • 抗CCR4抗体併用化学療法により寛解が得られた後に、臍帯血移植を行ったATLLの1例

    諏訪部 達也, 柴崎 康彦, 片桐 隆幸, 宮腰 淑子, 布施 香子, 小林 弘典, 牛木 隆志, 森山 雅人, 瀧澤 淳, 成田 美和子, 曽根 博仁, 増子 正義

    臨床血液   57 ( 6 )   776 - 776   2016.6

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • Splenomegaly and thrombosis risk in essential thrombocythemia: the mayo clinic experience

    Yasuhiko Shibasaki, Takayuki Katagiri, Hironori Kobayashi, Takashi Ushiki, Miwako Narita, Hirohito Sone, Tatsuo Furukawa, Masayoshi Masuko

    AMERICAN JOURNAL OF HEMATOLOGY   91 ( 5 )   E296 - E296   2016.5

     More details

    Language:English   Publishing type:Rapid communication, short report, research note, etc. (scientific journal)   Publisher:WILEY-BLACKWELL  

    DOI: 10.1002/ajh.24334

    Web of Science

    researchmap

  • アルブミン,フェリチン,CRPを用いたBiomarker indexは,造血幹細胞移植前患者に対するHCT‐CIとは独立した予後予測因子である

    諏訪部達也, 柴崎康彦, 宮腰淑子, 布施香子, 小林弘典, 牛木隆志, 森山雅人, 瀧澤淳, 成田美和子, 曽根博仁, 増子正義

    日本造血細胞移植学会総会プログラム・抄録集   38th   221   2016.2

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • 造血幹細胞移植患者のバイオクリーンルーム入室時の栄養管理の現状と課題

    曽根あずさ, 村山稔子, 柴崎康彦, 増子正義

    日本病態栄養学会誌(Web)   20 ( Supplement )   2016

  • Combination of Low Rate of gamma delta T Cells and High Rate of Regulatory T Cells after Allogeneic Stem Cell Transplantation Is a Poor Prognostic Factor for Patients with Hematological Neoplasm

    Yasuhiko Shibasaki, Syukuko Miyakoshi, Takayuki Katagiri, Kyoko Fuse, Hironori Kobayashi, Takashi Ushiki, Masato Moriyama, Jun Takizawa, Miwako Narita, Hirohito Sone, Masayoshi Masuko

    BLOOD   126 ( 23 )   2015.12

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER SOC HEMATOLOGY  

    Web of Science

    researchmap

  • 脳死両肺移植後の小腸DLBCL発症に対して化学療法施行後に気管支アスペルギローシスを発症した1例

    河本 啓介, 佐藤 征二郎, 根本 洋樹, 小林 弘典, 柴崎 康彦, 牛木 隆志, 森山 雅人, 瀧澤 淳, 成田 美和子, 土田 正則, 曽根 博仁, 増子 正義

    臨床血液   56 ( 11 )   2361 - 2361   2015.11

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • The usage of T cell receptor β-chain variable region of WT1 specific Cytotoxic T lymphocytes in CML patient treated WT1 peptide vaccination

    Iwaya Shunpei, Narita Miwako, Masuko Masayoshi, Nishizawa Yoshinori, Ida Tori, Oiwa Eri, Shibazaki Yasuhiko, Uchiyama Takayoshi, Sone Hirohito, Takahashi Masuhiro

    新潟大学保健学雑誌 = Journal of health sciences of Niigata University   12 ( 1 )   83 - 89   2015.9

     More details

    Language:Japanese   Publisher:新潟大学医学部保健学科  

    抗原特異的細胞傷害性T細胞(CTL)は抗腫瘍免疫療法において重要な役割を担っている。微量残存CML細胞を根絶するため,imatinib療法を4年間受けたCML症例にWT1ペプチドワクチンを投与した。混合リンパ球ペプチド培養(MLPC)を行い,WT1/MHC-tetramer+CD8+細胞の出現頻度の評価によって末梢血中のWT1特異的CTLの増幅効果の推移を確認した。その結果,WT1ペプチドワクチン投与を終了し6年経過した現在も,WT1特異的CTL はCD8陽性細胞中5-15x10^&lt;-6&gt;の頻度で検出され続けていることが確認された。CTLの検出の検討に加えて,長期間増幅されたWT1特異的CTLのT細胞受容体β鎖可変領域(TCRVβ)のレパトワを8回の解析を試みた。MLPC後,CD8+T細胞中のWT1特異的CTLの割合が高いwellについてレパトワ解析を行った。WT1ペプチドワクチンやMLPCには単一の9merのペプチドを使用したが,3種類のTCRVβの使用が見られた。imatinibとWT1ペプチドワクチン併用療法はCML症例においてWT1特異的CTLを長期間持続させる点で有効であることが確認された。さらに,本研究では,WT1特異的CTLにおいてはoligoclonalなTCRVβが使用されている可能性が示唆された。Antigen specific cytotoxic T lymphocytes (CTLs) play an important role in cancer immunotherapy. To eradicate tumor cells, we administrated WT1 peptide vaccine for a CML patient who was being treated imatinib therapy. The appearance of WT1 specific CTLs in peripheral blood was confirmed by evaluating the frequency of MHC/WT1 tetramer+CD8+ T cells by using mixed lymphocyte peptide culture (MLPC) system. After the cessation of vaccination, WT1 specific CTLs remained at the level of 5-15x10^&lt;-6&gt; in CD8+ T cells, which is lasting thereafter for 6 years. These cells showed cytotoxicity against WT1 peptide with MHC classⅠ restricted. In order to identification of T cell receptor β-chain variable region (TCRVβ) in CML patient received WT1 peptide vaccine, We also investigated the usage of T CVβof WT1 specific CTLs. MLPC cells with high proportion of CD8+ WT1 tetramer+ T cells were assessed for TCRVβ usage by using TCRVβ gene family specific monoclonal antibodies and flow cytometry. Cells from each well cultured by MLPC showed various types of TCRVβ repertoires from well to well. WT1 peptide vaccination for an imatinib pretreated CML patient is effective in terms of longterm generation of WT1 specific CTLs with cytotoxicity against WT1 peptide. The present study suggested that CTLs detected by MLPC possessed oligoclonal features of TCRVβ gene used, but not identical. Taken together, CTLs induced by tumor antigen specific peptide are potent for antitumor immunity.

    CiNii Article

    CiNii Books

    researchmap

    Other Link: http://hdl.handle.net/10191/38963

  • EBV関連疾患寛解後の全血EBV-DNA定量の再発予測の有用性に関する検討

    河本 啓介, 根本 洋樹, 笠見 卓哉, 片桐 隆幸, 小林 弘典, 柴崎 康彦, 増子 正義, 成田 美和子, 曽根 博仁, 大島 孝一, 瀧澤 淳

    日本リンパ網内系学会会誌   55   107 - 107   2015.6

     More details

    Language:Japanese   Publisher:(一社)日本リンパ網内系学会  

    researchmap

  • 再発時CCND1転座陽性となったCD5陽性MALTリンパ腫の1例

    根本 洋樹, 笠見 卓哉, 片桐 隆幸, 河本 啓介, 小林 弘典, 牛木 隆志, 柴崎 康彦, 森山 雅人, 増子 正義, 成田 美和子, 曽根 博仁, 瀧澤 淳, 大湊 絢, 張 大行, 尾山 徳秀, 福地 健郎, 竹内 賢吾, 中村 直哉, 栗田 大輔, 市川 理子, 大島 孝一

    日本リンパ網内系学会会誌   55   104 - 104   2015.6

     More details

    Language:Japanese   Publisher:(一社)日本リンパ網内系学会  

    researchmap

  • MYC転座とBCL2転座を認めたCD20陰性EBV陽性胃原発B細胞リンパ腫の一例

    笠見 卓哉, 根本 洋樹, 片桐 隆幸, 河本 啓介, 小林 弘典, 柴崎 康彦, 増子 正義, 丸田 美和子, 曽根 博仁, 瀧澤 淳, 橋口 俊洋, 栗田 大輔, 大島 孝一

    日本リンパ網内系学会会誌   55   106 - 106   2015.6

     More details

    Language:Japanese   Publisher:(一社)日本リンパ網内系学会  

    researchmap

  • 6 Hodgkin-like ATLL の1症例(Ⅰ.一般演題, 第55回下越内科集談会)

    鈴木 隆晴, 河本 啓介, 宮腰 淑子, 柴崎 康彦, 増子 正義, 曽根 博仁, 瀧澤 淳, 野本 信彦, 大島 孝一

    新潟医学会雑誌   129 ( 5 )   289 - 289   2015.5

     More details

    Language:Japanese   Publisher:新潟医学会  

    CiNii Article

    CiNii Books

    researchmap

    Other Link: http://search.jamas.or.jp/link/ui/2015374716

  • PNH型赤血球の出現を合併したEvans症候群の1例

    小林 弘典, 笠見 卓哉, 片桐 隆幸, 根本 洋樹, 河本 啓介, 牛木 隆志, 柴崎 康彦, 森山 雅人, 瀧澤 淳, 成田 美和子, 曽根 博仁, 亀崎 豊実, 増子 正義

    臨床血液   56 ( 5 )   550 - 551   2015.5

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • 妊娠を契機に診断されたUpshaw-Schulman症候群症例における第二子妊娠の周産期管理

    森山 雅人, 玉木 悦子, 松本 雅則, 石西 綾美, 松本 吉史, 冨永 麻理恵, 工藤 理沙, 安達 聡介, 生野 寿史, 高桑 好一, 宮腰 淑子, 小堺 貴司, 小林 弘典, 牛木 隆志, 柴崎 康彦, 増子 正義, 瀧澤 淳, 成田 美和子, 曽根 博仁, 西條 康夫

    日本血栓止血学会誌   26 ( 2 )   193 - 193   2015.4

     More details

    Language:Japanese   Publisher:(一社)日本血栓止血学会  

    researchmap

  • 臍帯血移植後,血漿HHV‐6DNA量が比較的低値でありながらHHV‐6脳炎を発症したEBウイルス関連リンパ増殖症(EBV‐LPD)の一例

    根本洋樹, 小林弘典, 笠見卓哉, 片桐隆幸, 河本啓介, 牛木隆志, 柴崎康彦, 森山雅人, 瀧澤淳, 成田美和子, 曽根博仁, 増子正義, 石原智彦, 西澤正豊

    日本造血細胞移植学会総会プログラム・抄録集   37th   306   2015.2

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • 造血幹細胞移植後28日目の末梢血好酸球数50/μl未満は予後不良因子である

    河本啓介, 柴崎康彦, 小林弘典, 牛木隆志, 森山雅人, 瀧澤淳, 成田美和子, 曽根博仁, 増子正義

    日本造血細胞移植学会総会プログラム・抄録集   37th   230   2015.2

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • MDSに対する同種移植によるMDS transplant risk indexの有用性

    片桐隆幸, 柴崎康彦, 小林弘典, 牛木隆志, 佐藤直子, 矢野敏雄, 森山雅人, 黒羽高志, 瀧澤淳, 橋本誠雄, 小池正, 曽根博仁, 古川達雄, 増子正義

    日本造血細胞移植学会総会プログラム・抄録集   37th   237   2015.2

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • 同種造血幹細胞移植における血清蛋白と発熱・炎症反応との関連性の検討

    森山雅人, 柴崎康彦, 増子正義, 根本洋樹, 片桐隆幸, 笠見卓哉, 河本啓介, 田中智之, 宮腰淑子, 小堺貴司, 小林弘典, 布施香子, 牛木隆志, 瀧澤淳, 曽根博仁, 西條康夫

    日本造血細胞移植学会総会プログラム・抄録集   37th   309   2015.2

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • 重症再生不良性貧血に対する免疫抑制療法中に長期の潜伏期を経て発症したレジオネラ肺炎の1例

    小林 弘典, 宮腰 淑子, 小堺 貴司, 柴崎 康彦, 森山 雅人, 増子 正義, 瀧澤 淳, 曽根 博仁, 田邊 嘉也

    臨床血液   55 ( 7 )   827 - 827   2014.7

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • MALTリンパ腫65例の臨床病理学的検討

    瀧澤 淳, 小林 弘典, 柴崎 康彦, 森山 雅人, 増子 正義, 曽根 博仁, 成田 美和子, 大湊 絢, 張 大行, 尾山 徳秀, 福地 健郎, 青木 定夫, 中村 直哉, 大島 孝一

    日本リンパ網内系学会会誌   54   101 - 101   2014.6

     More details

    Language:Japanese   Publisher:(一社)日本リンパ網内系学会  

    researchmap

  • MALTリンパ腫65例の臨床病理学的検討

    瀧澤 淳, 小林 弘典, 柴崎 康彦, 森山 雅人, 増子 正義, 曽根 博仁, 成田 美和子, 大湊 絢, 張 大行, 尾山 徳秀, 福地 健郎, 青木 定夫, 中村 直哉, 大島 孝一

    日本リンパ網内系学会会誌   54   91 - 91   2014.6

     More details

    Language:Japanese   Publisher:(一社)日本リンパ網内系学会  

    researchmap

  • Long term generation of WT1 specific cytotoxic T lymphocytes in CML case treated with WT1 peptide vaccine

    Iwaya Shunpei, Narita Miwako, Masuko Masayoshi, Nishizawa Yoshinori, Ida Tori, Oiwa Eri, Iwabuchi Minami, Uchiyama Takayoshi, Shibazaki Yasuhiko, Takizawa Jun, Sone Hirohito, Takahashi Masuhiro

    新潟大学保健学雑誌 = Journal of health sciences of Niigata University   11 ( 1 )   83 - 91   2014.3

     More details

    Language:Japanese   Publisher:新潟大学医学部保健学科  

    To clarify the effectiveness and safety of WT1 peptide vaccination against the residual CML cells, we started WT1 peptide vaccination in combination with regular dose of imatinib for a CML-CP patient who had been treated with 400 mg imatinib for 4 years but not achieved MMR. HLA-A*24:02-restricted mutant type WT1 peptide vaccination was undertaken 22 times totally. The appearance of WT1-specific CTLs in PB was confirmed by evaluating the frequency of MHC/WT1 tetramer+CD8+ T cells by using mixed lymphocyte peptide culture(MLPC)system every 4 weeks. WT1 tetramer+ cells detected by MLPC system were investigated for WT1 specific cytotoxicity. Bcr-abl transcripts have decreased to less than 500 copies by the administration of WT1 peptides every 4 weeks. After 7 months from the cessation of vaccination, transcripts decreased to the level of CMR, which is lasting thereafter Tumor antigen specific peptide vaccine therapy in combination with molecular targeted therapy is one of the potent methods for eradicating cancer stem cells.

    CiNii Article

    CiNii Books

    researchmap

    Other Link: http://hdl.handle.net/10191/38944

  • 同種造血幹細胞移植における血清蛋白と発熱・炎症所見との関連性の検討

    松本瑛生, 森山雅人, 平安座依子, 田中智之, 宮腰淑子, 小堺貴司, 小林弘典, 布施香子, 柴崎康彦, 増子正義, 瀧澤淳, 古川達雄, 曽根博仁, 西條康夫

    日本造血細胞移植学会総会プログラム・抄録集   36th   360   2014.2

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • 再発後の再移植後の汎血球減少期にgrade4の重症心不全を併発するも救命しえた急性骨髄性白血病

    宮腰淑子, 柴崎康彦, 布施香子, 森山雅人, 古川達雄, 勝海悟郎, 小田雅人, 渡部裕, 柏村健, 南野徹, 曽根博仁, 増子正義

    日本造血細胞移植学会総会プログラム・抄録集   36th   341   2014.2

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • 急性骨髄性白血病及び骨髄異形成症候群に対する同種造血幹細胞移植成績に移植前骨髄の芽球率が与える影響

    柴崎康彦, 宮越淑子, 小堺貴司, 小林弘典, 森山雅人, 古川達雄, 増子正義, 曽根博仁

    日本造血細胞移植学会総会プログラム・抄録集   36th   331   2014.2

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • 同種造血幹細胞移植関連口腔粘膜炎の危険因子とsystematic oral managementの役割

    勝良剛詞, 増子正義, 古川達雄, 曽我麻里恵, 柴崎康彦, 森山雅人, 小堺貴司, 千葉香, 高木律男, 林孝文

    日本造血細胞移植学会総会プログラム・抄録集   36th   342   2014.2

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • MYC転座陽性アグレッシブB細胞リンパ腫15例の後方視的解析

    瀧澤 淳, 宮腰 淑子, 田中 智之, 小堺 貴司, 小林 弘典, 柴崎 康彦, 森山 雅人, 増子 正義, 曽根 博仁

    日本内科学会雑誌   103 ( Suppl. )   174 - 174   2014.2

     More details

    Language:Japanese   Publisher:(一社)日本内科学会  

    researchmap

  • ドナーKIRハプロタイプBはATG不使用同種造血幹細胞移植において重症急性GVHDの危険因子となる可能性がある

    細貝亮介, 今井千速, 柴崎康彦, 増子正義, 古川達雄

    日本造血細胞移植学会総会プログラム・抄録集   36th   2014

  • Early Responses At 3 Months and 12 Months After Starting Imatinib As Predictive Factors For The Achievement Of Deep MR In Japanese CML Patients

    Masayoshi Masuko, Tatsuo Furukawa, Tadashi Koike, Kazue Takai, Koichi Nagai, Kenji Kishi, Yoshinobu Seki, Hoyu Takahashi, Sadao Aoki, Takashi Kozakai, Yasuhiko Shibasaki, Takashi Ushiki, Ken Toba, Miwako Narita, Masuhiro Takahashi, Hirohito Sone, Akira Shibata

    BLOOD   122 ( 21 )   2013.11

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER SOC HEMATOLOGY  

    DOI: 10.1182/blood.V122.21.2744.2744

    Web of Science

    researchmap

  • 46 多彩な画像所見を呈し肝生検で確診した血管内リンパ腫の1例(Ⅰ.一般演題, 第37回リバーカンファレンス)

    眞水 麻以子, 西山 佑樹, 畠野 雄也, 阿部 寛幸, 上村 顕也, 高橋 祥史, 水野 研一, 竹内 学, 川合 弘一, 野本 実, 青柳 豊, 柴崎 康彦, 瀧澤 淳, 曽根 博仁, 石黒 敬信, 堅田 慎一, 西澤 正豊, 高野 徹

    新潟医学会雑誌   127 ( 10 )   581 - 582   2013.10

     More details

    Language:Japanese   Publisher:新潟医学会  

    CiNii Article

    CiNii Books

    researchmap

    Other Link: http://search.jamas.or.jp/link/ui/2014161062

  • 妊娠を契機に診断された新規の遺伝子変異を伴うUpshaw-Schulman症候群(USS)の一例

    小堺 貴司, 森山 雅人, 布施 一郎, 柴崎 康彦, 増子 正義, 瀧澤 淳, 鳥羽 健, 吉田 邦彦, 小亀 浩市, 宮田 敏行, 松本 雅則, 藤村 吉博, 曽根 博仁

    日本血栓止血学会誌   24 ( 2 )   213 - 213   2013.4

     More details

    Language:Japanese   Publisher:(一社)日本血栓止血学会  

    researchmap

  • 当科における悪性リンパ腫と合併する悪性腫瘍の後方視的検討

    宮腰 淑子, 瀧澤 淳, 田中 智之, 布施 香子, 小堺 貴司, 柴崎 康彦, 森山 雅人, 増子 正義, 曽根 博仁, 尾山 徳秀, 大島 孝一

    日本リンパ網内系学会会誌   53   113 - 113   2013.4

     More details

    Language:Japanese   Publisher:(一社)日本リンパ網内系学会  

    researchmap

  • 治療後3ヵ月の血清IL-2R値はびまん性大細胞型B細胞性リンパ腫の長期予後を反映する

    田中 智之, 瀧澤 淳, 宮腰 淑子, 小堺 貴司, 布施 香子, 柴崎 康彦, 森山 雅人, 増子 正義, 曽根 博仁, 尾山 徳秀, 大島 孝一

    日本リンパ網内系学会会誌   53   120 - 120   2013.4

     More details

    Language:Japanese   Publisher:(一社)日本リンパ網内系学会  

    researchmap

  • Nelarabine/Fludarabine併用療法により寛解を得たT-PLLの一例

    布施 香子, 瀧澤 淳, 宮腰 淑子, 田中 智之, 小堺 貴司, 柴崎 康彦, 森山 雅人, 増子 正義, 曽根 博仁, 三好 寛明, 大島 孝一, 横濱 章彦

    日本リンパ網内系学会会誌   53   151 - 151   2013.4

     More details

    Language:Japanese   Publisher:(一社)日本リンパ網内系学会  

    researchmap

  • 腎移植後の腎障害合併MDS患者に対して減量フルダラビン,ブスルファンによる前処置による骨髄非破壊的造血幹細胞移植を行った一例

    西脇邦恵, 岡塚貴世志, 宮腰淑子, 柴崎康彦, 増子正義, 森山雅人, 瀧澤淳, 中川由紀, 斎藤和英, 鳴海福星, 高橋公太, 曽根博仁, 古川達雄

    日本造血細胞移植学会総会プログラム・抄録集   35th   265   2013.2

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • 骨髄破壊的前処置による同種造血幹細胞移植後早期の末梢血リンパ球数が予後に与える影響

    柴崎康彦, 増子正義, 森山雅人, 岡塚貴世志, 布施香子, 小堺貴司, 宮越淑子, 田中智之, 鳥羽健, 曽根博仁, 古川達雄

    日本造血細胞移植学会総会プログラム・抄録集   35th   218   2013.2

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • Disease Risk Index(DRI)が造血器腫瘍に対する同種造血幹細胞移植成績に与える影響

    田中智之, 増子正義, 小堺貴司, 布施香子, 柴崎康彦, 岡塚貴世志, 森山雅人, 宮腰淑子, 瀧澤淳, 鳥羽健, 曽根博仁, 古川達雄

    日本造血細胞移植学会総会プログラム・抄録集   35th   212   2013.2

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • Correlation Between Imatinib Trough Concentration and Long-Term Tolerability in CML Patients

    Masayoshi Masuko, Tatsuo Furukawa, Toyoyuki Tanaka, Syukuko Miyakoshi, Takashi Kozakai, Kyoko Fuse, Yasuhiko Shibasaki, Kazue Takai, Yoshinobu Seki, Masashi Kobayashi, Koichi Nagai, Hoyu Takahashi, Kenji Kishi, Miwako Narita, Masuhiro Takahashi, Tadashi Koike, Akira Shibata

    BLOOD   120 ( 21 )   2012.11

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER SOC HEMATOLOGY  

    Web of Science

    researchmap

  • 全身結節性皮疹で発症したtriple hit lymphomaの一例

    小堺貴司, 瀧澤淳, 北嶋俊樹, 東村益孝, 柴崎康彦, 阿部崇, 森山雅人, 増子正義, 古川達雄, 鳥羽健, 相澤義房, 木村芳三, 大島孝一

    日本リンパ網内系学会会誌   51   96   2011.6

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • 2 皮膚に髄外病変を認めたinv (16) を有する急性骨髄性白血病の1例(一般演題,第51回下越内科集談会)

    柴田怜, 柴崎康彦, 森山雅人, 滝澤淳, 増子正義, 古川達雄, 鳥羽健, 相澤義房

    新潟医学会雑誌   125 ( 5 )   291 - 291   2011.5

  • 7 発熱, 好酸球増多, 皮疹で発症した悪性リンパ腫の1例(一般演題,第50回下越内科集談会)

    水澤健, 東村益孝, 百都亜矢子, 柴崎康彦, 森山雅人, 瀧澤淳, 鳥羽健, 青木定夫, 相澤義房

    新潟医学会雑誌   124 ( 6 )   350 - 351   2010.6

  • late rejectionを来したHLA class1拒絶方向一座不一致同種末梢血幹細胞移植例

    田中智之, 柴崎康彦, 森山雅人, 小林弘典, 増子正義, 古川達雄, 鳥羽健, 相澤義房

    日本造血細胞移植学会総会プログラム・抄録集   32nd   240   2010

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • 3 腫瘍随伴性天疱瘡を合併した濾胞性リンパ腫の1例(一般演題,第49回下越内科集談会)

    123 ( 7 )   374 - 374   2009.7

  • 同種造血幹細胞移植後の生着症候群による体液貯留に対するハンプ(カルペリチド)の有用性

    森山雅人, 柴崎康彦, 阿部崇, 矢野敏雄, 黒羽高志, 増子正義, 瀧澤淳, 鳥羽健, 古川達雄, 相澤義房

    日本内科学会雑誌   98   155   2009.2

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • Imatinib治療中にMonosomy 7を有するMDSを発症したCML症例

    狩俣かおり, 百都亜矢子, 柴崎康彦, 森山雅人, 増子正義, 鳥羽健, 古川達雄, 相澤義房

    臨床血液   49 ( 9 )   1016   2008.9

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • 同種造血幹細胞移植後にIdiopathic Pneumonia Syndromeをきたした3例の血清サイトカインの推移

    阿部 崇, 牛木 隆志, 柴崎 康彦, 東村 益孝, 岡塚 貴世志, 黒羽 高志, 鳥羽 健, 相澤 義房, 増子 正義, 古川 達雄, 飯酒盃 訓充, 永井 孝一, 関 義信

    臨床血液   49 ( 9 )   1219 - 1219   2008.9

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • Human osteoblasts as well as mesenchymal stem cells suppress allogenic T-CELLS

    Toshiki Kitajima, Masayoshi Masuko, Tori Kurasaki, Yasuhiko Shibasaki, Tatsuo Furukawa, Ken Toba, Yoshifusa Aizawa

    EXPERIMENTAL HEMATOLOGY   36 ( 7 )   S83 - S84   2008.7

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:ELSEVIER SCIENCE INC  

    Web of Science

    researchmap

  • 2 中枢神経浸潤の後,広範な末梢神経障害を呈した鼻中隔原発非ホジキンリンパ腫の1例(I.一般演題,第49回新潟造血器腫瘍研究会)

    小泉 健, 関 義信, 柴崎 康彦, 岸 賢治, 関根 輝夫, 牧野 邦比古, 半藤 英, 若木 邦彦

    新潟医学会雑誌   121 ( 12 )   716 - 716   2007.12

     More details

    Language:Japanese   Publisher:新潟大学  

    CiNii Article

    CiNii Books

    researchmap

    Other Link: http://search.jamas.or.jp/link/ui/2008162825

  • 2 Asian variant IVLの1例(第48回新潟造血器腫瘍研究会)

    柴崎 康彦, 瀧澤 淳, 矢野 敏雄, 増子 正義, 土山 準二郎, 青木 定夫, 鳥羽 健, 中村 直哉, 飯酒盃 訓充

    新潟医学会雑誌   121 ( 3 )   173 - 174   2007.3

     More details

    Language:Japanese   Publisher:新潟大学  

    CiNii Article

    CiNii Books

    researchmap

    Other Link: http://search.jamas.or.jp/link/ui/2007306260

  • Human Osteoblasts and Mesenchymal Stem Cells Derived from Bone Marrow Support the Expansion of CD34^+ Hematopoetic Progenitor Cells

    SIBASAKI Yasuhiko

    Niigata medical journal   120 ( 8 )   464 - 474   2006.8

     More details

    Language:Japanese   Publisher:Niigata University  

    CiNii Article

    CiNii Books

    researchmap

    Other Link: http://hdl.handle.net/10191/19864

  • 1 Trilineage leukemiaの4例(第47回新潟造血器腫瘍研究会)

    北嶋 俊樹, 柴崎 康彦, 矢野 敏雄, 増子 正義, 瀧澤 淳, 八木沢 久美子, 鳥羽 健, 相澤 義房, 橋本 誠雄, 古川 達雄

    新潟医学会雑誌   119 ( 6 )   370 - 371   2005.6

     More details

    Language:Japanese   Publisher:新潟大学  

    CiNii Article

    CiNii Books

    researchmap

    Other Link: http://search.jamas.or.jp/link/ui/2006006539

  • 1 DICにて発見された進行胃癌合併妊娠分娩症例の1例(第9回DIC研究会)

    倉林 工, 石井 桂介, 笹原 淳, 鈴木 美奈, 高桑 好一, 田中 憲一, 柴崎 康彦, 橋本 誠雄, 布施 一郎, 野本 実, 成澤 林太郎, 小澤 常徳, 関塚 直人, 関塚 正昭

    新潟医学会雑誌   116 ( 11 )   566 - 566   2002.11

     More details

    Language:Japanese   Publisher:新潟大学  

    CiNii Article

    CiNii Books

    researchmap

    Other Link: http://search.jamas.or.jp/link/ui/2003169748

  • 28)特発性門脈圧亢進症(IPH)における肝動脈および門脈血流の不均等分布について(I.一般演題, 第24回リバーカンファレンス総会 )

    和栗 暢生, 杉谷 鈴子, 塩路 和彦, 柴崎 康彦, 五十嵐 正人, 須田 剛士, 渡辺 雅史, 野本 実, 市田 隆文, 青柳 豊, 朝倉 均, 山本 賢

    新潟医学会雑誌   115 ( 7 )   334 - 334   2001.7

     More details

    Language:Japanese   Publisher:新潟医学会  

    CiNii Article

    CiNii Books

    researchmap

  • 6)基礎疾患を認めない低レニン低アルドステロン症の一例(一般演題, 第40回下越内科集談会)

    柴崎 康彦, 鈴木 克典, 大山 泰郎, 長沼 景子, 河内 文女, 鈴木 亜希子, 金子 晋, 中川 理, 相澤 義房

    新潟医学会雑誌   114 ( 12 )   480 - 481   2000.12

     More details

    Language:Japanese   Publisher:新潟医学会  

    CiNii Article

    CiNii Books

    researchmap

    Other Link: http://search.jamas.or.jp/link/ui/2001134885

▶ display all

Presentations

  • 骨髄異形成症候群と低悪性度B細胞リンパ腫を合併し、多彩な合併症を呈した1例

    海發 茜, 小堺 貴司, 田村 秀, 片桐 隆幸, 河本 啓介, 難波 亜矢子, 布施 香子, 牛木 隆志, 柴崎 康彦, 森山 雅人, 瀧澤 淳, 成田 美和子, 曽根 博仁, 増子 正義

    臨床血液  2019.10  (一社)日本血液学会-東京事務局

     More details

    Event date: 2019.10

    Language:Japanese  

    researchmap

  • Hodgkin lymphomaとAnaplastic large cell lymphomaの鑑別が困難であった巨大縦隔腫瘤を呈した1例

    河本 啓介, 鈴木 隆晴, 海發 茜, 田村 秀, 片桐 隆之, 難波 亜矢子, 布施 香子, 柴崎 康彦, 増子 正義, 曽根 博仁, 三好 寛明, 大島 孝一, 瀧澤 淳

    日本リンパ網内系学会会誌  2019.5  (一社)日本リンパ網内系学会

     More details

    Event date: 2019.5

    Language:Japanese  

    researchmap

  • 非寛解期末梢血幹細胞移植後に通常量5‐AZA療法を施行し,寛解を維持しているEVI‐1陽性AMLの一例

    田村秀, 柴崎康彦, 上村駿, 笠見卓哉, 海發茜, 今西明, 片桐隆幸, 難波亜矢子, 河本啓介, 牛木隆志, 布施香子, 瀧澤淳, 成田美和子, 曽根博仁, 増子正義

    日本造血細胞移植学会総会プログラム・抄録集  2019.2 

     More details

    Event date: 2019.2

    Language:Japanese  

    researchmap

  • 3度目の同種造血細胞移植後ポナチニブ維持療法を行い,寛解を維持している再発・難治Ph陽性ALL

    海發茜, 柴崎康彦, 諏訪部達也, 笠見卓哉, 田村秀, 片桐隆幸, 河本啓介, 難波亜矢子, 布施香子, 牛木隆志, 森山雅人, 瀧澤淳, 成田美和子, 曽根博仁, 増子正義

    日本造血細胞移植学会総会プログラム・抄録集  2019.2 

     More details

    Event date: 2019.2

    Language:Japanese  

    researchmap

  • ATRA・ATO併用療法により寛解を維持している再発性治療関連急性前骨髄白血病の1例

    前田 愁一郎, 布施 香子, 諏訪部 達也, 笠見 卓哉, 河本 啓介, 田中 智之, 難波 亜矢子, 小林 弘典, 柴崎 康彦, 瀧澤 淳, 成田 美和子, 曽根 博仁, 増子 正義

    臨床血液  2018.11  (一社)日本血液学会-東京事務局

     More details

    Event date: 2018.11

    Language:Japanese  

    researchmap

  • 同種造血幹細胞移植における強化口腔ケアは生着後の血流感染を減少させる(Intensive oral care can reduce blood stream infection post neutrophil engraftment in allogeneic HCT)

    諏訪部 達也, 布施 香子, 勝良 剛詞, 田中 恵子, 片桐 隆幸, 田中 智之, 牛木 隆志, 柴崎 康彦, 成田 美和子, 曽根 博仁, 増子 正義

    臨床血液  2018.9  (一社)日本血液学会-東京事務局

     More details

    Event date: 2018.9

    Language:English  

    researchmap

  • 寛解期急性白血病に対する同種移植のドナーソース別入院費の比較(Hospitalization costs of allo-HCT among donor sources for acute leukemia in complete remission)

    難波 亜矢子, 柴崎 康彦, 上村 駿, 諏訪部 達也, 片桐 隆幸, 田中 智之, 布施 香子, 成田 美和子, 曽根 博仁, 増子 正義

    臨床血液  2018.9  (一社)日本血液学会-東京事務局

     More details

    Event date: 2018.9

    Language:English  

    researchmap

  • 単一施設におけるATGとPTCYを用いた半合致移植の後方視解析(Clinical analysis of haploidentical transplantation using ATG and PTCY in single institute)

    田中 智之, 上村 駿, 海發 茜, 田村 秀, 諏訪部 達也, 片桐 隆幸, 河本 啓介, 布施 香子, 牛木 隆志, 柴崎 康彦, 瀧澤 淳, 成田 美和子, 曽根 博仁, 増子 正義

    臨床血液  2018.9  (一社)日本血液学会-東京事務局

     More details

    Event date: 2018.9

    Language:English  

    researchmap

  • 濾胞性リンパ腫初回診断時におけるアグレッシブリンパ腫への形質転換予測(MYC copy number predicts histologic transformation of follicular lymphoma to aggressive lymphoma)

    桐生 真依子, 河本 啓介, 鈴木 隆晴, 田村 秀, 上村 駿, 海發 茜, 諏訪部 達也, 今西 明, 笠見 卓哉, 根本 洋樹, 片桐 隆幸, 田中 智之, 難波 亜矢子, 布施 香子, 柴崎 康彦, 増子 正義, 曽根 博仁, 三好 寛明, 瀬戸 加大, 大島 孝一, 瀧澤 淳

    臨床血液  2018.9  (一社)日本血液学会-東京事務局

     More details

    Event date: 2018.9

    Language:English  

    researchmap

  • ビタミンD3産生性と考えられるALK陰性未分化大細胞リンパ腫の1例

    水戸部 正樹, 河本 啓介, 鈴木 隆晴, 難波 亜矢子, 柴崎 康彦, 増子 正義, 曽根 博仁, 三好 寛明, 大島 孝一, 瀧澤 淳

    日本リンパ網内系学会会誌  2018.5  (一社)日本リンパ網内系学会

     More details

    Event date: 2018.5

    Language:Japanese  

    researchmap

  • G-CSFを産生し初回治療中に再発したびまん性大細胞型B細胞性リンパ腫の1例

    笠見 卓哉, 河本 啓介, 鈴木 隆晴, 田中 智之, 布施 香子, 柴崎 康彦, 増子 正義, 成田 美和子, 曽根 博仁, 大島 孝一, 瀧澤 淳

    日本リンパ網内系学会会誌  2018.5  (一社)日本リンパ網内系学会

     More details

    Event date: 2018.5

    Language:Japanese  

    researchmap

  • GDP療法がtriple-hit lymphomaの救援療法として有効であった1例

    水戸部 正樹, 河本 啓介, 鈴木 隆晴, 田村 秀, 小堺 貴司, 難波 亜矢子, 諏訪部 達也, 笠見 卓哉, 田中 智之, 布施 香子, 柴崎 康彦, 増子 正義, 曽根 博仁, 大島 孝一, 瀧澤 淳

    臨床血液  2018.5  (一社)日本血液学会-東京事務局

     More details

    Event date: 2018.5

    Language:Japanese  

    researchmap

  • 多職種連携チーム医療が著効した食道慢性GVHDの一例

    難波亜矢子, 上村駿, 諏訪部達也, 笠見卓哉, 河本啓介, 河本啓介, 田中智之, 小林弘典, 布施香子, 小師優子, 真柄仁, 高昌良, 冨永顕太郎, 橋本哲, 横山純二, 柴崎康彦, 柴崎康彦, 瀧澤淳, 曽根博仁, 増子正義

    日本造血細胞移植学会総会プログラム・抄録集  2017.12 

     More details

    Event date: 2017.12

    Language:Japanese  

    researchmap

  • マーカー染色体が急性骨髄性白血病に対する同種造血細胞移植成績に与える影響

    田中智之, 布施香子, 諏訪部達也, 笠見卓哉, 河本啓介, 河本啓介, 牛木隆志, 森山雅人, 柴崎康彦, 柴崎康彦, 瀧澤淳, 成田美和子, 曽根博仁, 増子正義, 増子正義

    日本造血細胞移植学会総会プログラム・抄録集  2017.12 

     More details

    Event date: 2017.12

    Language:Japanese  

    researchmap

  • HLA半合致移植後AMLとして再発したB-ALLの1例

    小堺 貴司, 田村 秀, 布施 香子, 柴崎 康彦, 瀧澤 淳, 曽根 博仁, 増子 正義

    臨床血液  2017.11  (一社)日本血液学会-東京事務局

     More details

    Event date: 2017.11

    Language:Japanese  

    researchmap

  • 抗原特異的細胞傷害性T細胞(CTL)の増幅と機能の検討

    小川 彩空, 増子 正義, 後藤 若奈, 内山 孝由, 橋本 誠雄, 柴崎 康彦, 瀧澤 淳, 成田 美和子

    日臨技北日本支部医学検査学会抄録集  2017.10  日臨技北日本支部医学検査学会

     More details

    Event date: 2017.10

    Language:Japanese  

    researchmap

  • Clinical Significance of MYC, BCL2 and BCL6 Rearrangement and Protein Expression in GCB and Non-GCB Type Diffuse Large B-Cell Lymphoma Invited

    Kawamoto Keisuke, Takizawa Jun, Miyoshi Hiroaki, Yoshida Noriaki, Shibasaki Yasuhiko, Masuko Masayoshi, Sone Hirohito, Nakamura Naoya, Ohshima Koichi

    BLOOD  2015.12 

     More details

    Event date: 2015.12

    Language:English  

    researchmap

  • Log Reduction Levels of WT1 mRNA Expression in BM after Chemotherapies Are Predictive Markers of Good Prognosis in AML Patients Achieved CR after Induction Therapy

    Yasuhiko Shibasaki, Yoshinobu Seki, Tomoyuki Tanaka, Syukuko Miyakoshi, Kyoko Fuse, Takashi Kozakai, Hironori Kobayashi, Takashi Ushiki, Takashi Abe, Toshio Yano, Masato Moriyama, Takashi Kuroha, Noriatsu Isahai, Jun Takizawa, Miwako Narita, Satoru Koyama, Tatsuo Furukawa, Hirohito Sone, Masayoshi Masuko

    BLOOD  2014.12  AMER SOC HEMATOLOGY

     More details

    Event date: 2014.12

    Language:English  

    researchmap

  • Imaging of Body Iron Stores in Transfusion-Dependent Patients By Liver Dual-Energy CT

    Hironori Kobayashi, Norihiko Yoshimura, Takashi Ushiki, Yasuhiko Shibasaki, Masato Moriyama, Jun Takizawa, Miwako Narita, Hirohito Sone, Masayoshi Masuko

    BLOOD  2014.12  AMER SOC HEMATOLOGY

     More details

    Event date: 2014.12

    Language:English  

    researchmap

▶ display all

Awards

  • Young Investigator ASH Travel Award 2009

    2009.12   JALSG  

     More details

Research Projects

  • 同種造血細胞移植の再発率低下を目指したリハビリテーション法の確立

    Grant number:20K11153

    2020.4 - 2023.3

    System name:科学研究費助成事業 基盤研究(C)

    Research category:基盤研究(C)

    Awarding organization:日本学術振興会

    柴崎 康彦, 森下 慎一郎, 増子 正義

      More details

    Grant amount:\4290000 ( Direct Cost: \3300000 、 Indirect Cost:\990000 )

    昨年度に引き続き、同種造血細胞移植後の腫瘍免疫動態を評価を行った。昨年度はHLA半合致移植を中心に解析を行ったが、本年度は同種造血細胞移植を行った造血器腫瘍患者全例を対象として、マルチカラーフローサイトメトリー法を併用し、同種造血細胞移植後30日前後の免疫動態について評価を行った。
    その結果、移植後30日時点でのCD8陽性ナイーブT細胞の比率が低く、T-EMRA細胞比率が多い症例で重症急性GVHD発症症例が有意に多いことが判明した。この傾向はドナー種類(末梢血・骨髄・臍帯血)によらず同様であった。このことは、重症急性GVHDを発症する症例は発症前から細胞障害活性を持つT細胞比率が高いことを示している。今回の結果は、aGVHDの発症を予測し、より適切なタイミングでの治療介入を行うことへ向けた重要な所見であると考えられた。
    また、本年度は新たに内皮活性化およびストレス指数(EASIX)が予後に与える影響についても解析を行った。適切なリハビリテーションにより、血管内皮機能や血小板活性化の改善が認められるとの報告があることから、EASIXとリハビリテーション、筋肉量との関連性を調べることが重要と考えられる。特に移植前のEASIXのみならず、移植後のEASIXが予後に与える影響について研究を進めており、移植後1年時点でのEASIX(EASIX-1year)がその後の非再発死亡に対する有意な予後予測因子であることを発見した。本研究成果は今後、国際学会での発表も視野に研究を進めているところである。
    移植成績には様々な要因があるため、適切な予後予測因子を同定することがリハビリテーション介入において重要である。そのため、同種造血細胞移植全般の予後予測についても並行して研究を進めている。

    researchmap

  • Establishment of evaluation method of tumor immunity for application of immune checkpoint inhibitor to AML/MDS

    Grant number:17K09006

    2017.4 - 2020.3

    System name:Grants-in-Aid for Scientific Research

    Research category:Grant-in-Aid for Scientific Research (C)

    Awarding organization:Japan Society for the Promotion of Science

    Shibasaki Yasuhiko

      More details

    Grant amount:\4680000 ( Direct Cost: \3600000 、 Indirect Cost:\1080000 )

    We recruited patients of myelodysplastic syndrome (MDS) and acute myeloid leukemia with myelodysplastic changes (AML-MRC) in this study. Using paired samples of bone marrow (BM) and peripheral blood (PB), we detected WT1-specific cytotoxic T cell (CTL) clones which were amplified specifically for the WT1 peptide antigen by the MLPC method, and the amount of these clones was evaluated.
    Sixty-seven percent of MDS/AML-MRC patients had functional WT1-specific CTL clones in BM. The ratio of CTL clones in BM was about 10 times higher than that in PB. These results show that the site of tumor immunity targeting WT1 is mainly in BM, and there are more patients than previously suggested who might effective for tumor immunotherapy with WT1 peptide vaccines and immune checkpoint inhibitors.

    researchmap